WO2015037720A1 - Muscle repair promoter - Google Patents
Muscle repair promoter Download PDFInfo
- Publication number
- WO2015037720A1 WO2015037720A1 PCT/JP2014/074291 JP2014074291W WO2015037720A1 WO 2015037720 A1 WO2015037720 A1 WO 2015037720A1 JP 2014074291 W JP2014074291 W JP 2014074291W WO 2015037720 A1 WO2015037720 A1 WO 2015037720A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- milk
- muscle synthesis
- casein
- whey
- Prior art date
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 138
- 230000008439 repair process Effects 0.000 title abstract description 6
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 110
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 110
- 235000021119 whey protein Nutrition 0.000 claims abstract description 105
- 235000018102 proteins Nutrition 0.000 claims abstract description 101
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 101
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 101
- 102000011632 Caseins Human genes 0.000 claims abstract description 87
- 108010076119 Caseins Proteins 0.000 claims abstract description 87
- 239000000203 mixture Substances 0.000 claims abstract description 73
- 230000001737 promoting effect Effects 0.000 claims abstract description 54
- 238000010521 absorption reaction Methods 0.000 claims abstract description 45
- 230000015572 biosynthetic process Effects 0.000 claims description 129
- 238000003786 synthesis reaction Methods 0.000 claims description 129
- 102000014171 Milk Proteins Human genes 0.000 claims description 80
- 108010011756 Milk Proteins Proteins 0.000 claims description 80
- 235000021239 milk protein Nutrition 0.000 claims description 80
- 235000013336 milk Nutrition 0.000 claims description 60
- 239000008267 milk Substances 0.000 claims description 60
- 210000004080 milk Anatomy 0.000 claims description 60
- 235000013305 food Nutrition 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 26
- 235000020124 milk-based beverage Nutrition 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 238000004806 packaging method and process Methods 0.000 claims description 20
- 230000037396 body weight Effects 0.000 claims description 18
- 235000020185 raw untreated milk Nutrition 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 14
- 235000012054 meals Nutrition 0.000 claims description 13
- 235000021243 milk fat Nutrition 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 235000008476 powdered milk Nutrition 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000012549 training Methods 0.000 claims description 9
- 235000020200 pasteurised milk Nutrition 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 235000019543 dairy drink Nutrition 0.000 claims 1
- 235000021075 protein intake Nutrition 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 6
- 235000013361 beverage Nutrition 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- 241000700159 Rattus Species 0.000 description 18
- 230000009182 swimming Effects 0.000 description 18
- 239000000843 powder Substances 0.000 description 16
- 229920005560 fluorosilicone rubber Polymers 0.000 description 14
- 101150100968 fsr gene Proteins 0.000 description 14
- 238000010438 heat treatment Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 210000002027 skeletal muscle Anatomy 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 5
- 102000008934 Muscle Proteins Human genes 0.000 description 5
- 108010074084 Muscle Proteins Proteins 0.000 description 5
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 5
- 239000005862 Whey Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013861 fat-free Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000003505 heat denaturation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000007696 Kjeldahl method Methods 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000000476 body water Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000020121 low-fat milk Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 235000021260 warm beverage Nutrition 0.000 description 2
- 235000021269 warm food Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 206010065713 Gastric Fistula Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012813 breadcrumbs Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000012839 cake mixes Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000021557 concentrated beverage Nutrition 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- -1 etc.) Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 235000014109 instant soup Nutrition 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000020191 long-life milk Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 235000014059 processed cheese Nutrition 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 235000014268 sports nutrition Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
- A23C9/1512—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins containing isolated milk or whey proteins, caseinates or cheese; Enrichment of milk products with milk proteins in isolated or concentrated form, e.g. ultrafiltration retentate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
Definitions
- the present invention relates to muscle synthesis promoters for subjects in need of immediate protein absorption.
- Whey protein has a high rate (absorption time) from ingestion to digestion and absorption (short time) and contains a lot of BCAA (branched chain amino acids: valine, leucine, isoleucine), thus preventing muscle fatigue, It is said that muscles can be strengthened efficiently.
- BCAA branched chain amino acids: valine, leucine, isoleucine
- casein protein is slowly and continuously metabolized compared to whey protein, so the rate from oral ingestion to digestion absorption (absorption rate) is slow (longer time) and needs immediate absorption. Is said to be unsuitable (see Patent Document 1). Therefore, whey protein is mainly used as protein powder.
- a mixed protein in which whey protein having high absorption and casein protein to be continuously absorbed are mixed at 1: 1 has been developed (for example, DNS protein slow loading). ).
- whey protein has low heat resistance (thermal stability), it undergoes thermal denaturation and tends to aggregate due to heating.
- protein powders are not recommended for consumption other than being dissolved in water. Therefore, protein powder remains powdery and cannot be said to have high palatability.
- the whey protein is hardened by heat denaturation and there is a problem that the absorption efficiency is lowered.
- an object of the present invention is to provide a muscle synthesis (enhancement) promoter having an immediate effect of promoting muscle synthesis equivalent to that of whey protein.
- a muscle synthesis promoter for a subject in need of immediate protein absorption comprising a milk protein mixture containing casein protein and whey protein as an active ingredient, and the amount of casein protein relative to whey protein
- a muscle synthesis promoter having a ratio (casein protein / whey protein) of 2 to 20.
- the muscle synthesis promoter described in 1. (4) The muscle synthesis promoter according to any one of (1) to (3) above, wherein the subject in need of immediate protein absorption is a subject to exercise. (5) The muscle synthesis promoter according to (4) above, wherein the exercise is muscle training. (6) The muscle synthesis promoter according to any one of (1) to (5), which is in a liquid form.
- a packaged container-packed milk drink that is provided with an action for promoting muscle synthesis by immediate protein absorption.
- a method for producing a packaged-packed milk beverage comprising a step of adding to one or more selected from the group consisting of milk and a step of heat sterilization, wherein the milk protein mixture is 8 g /
- a milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is taken by a subject who needs immediate absorption of the protein
- a method of promoting muscle synthesis comprising: (11) A milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is taken by a subject who needs immediate absorption of the protein.
- a method for promoting muscle synthesis comprising: (12) The method for promoting muscle synthesis according to (10) or (11) above, wherein the milk protein mixture is ingested so that the total protein amount is 0.13 to 0.7 g / kg body weight per serving. (13) The method for promoting muscle synthesis according to (12), wherein the milk protein mixture is ingested so that the total protein amount of the milk protein mixture is 8 to 40 g per serving. (14) The method for promoting muscle synthesis according to any one of the above (10) to (13), comprising ingesting the milk protein mixture in a heated liquid form to a subject in need of immediate absorption of the protein.
- the muscle synthesis promoter of the present invention has an immediate effect of promoting muscle synthesis equivalent to that of whey protein, and has higher heat resistance and better processability than using whey protein alone. Therefore, the muscle synthesis promoter of the present invention is advantageous in that it can be expected to have an immediate effect of promoting muscle synthesis and can be provided as an inexpensive product form that can be mass-produced commercially.
- FIG. 1 shows the skeletal muscle synthesis rate (FSR) in the triceps surae muscle and the hyfuku muscle when orally ingesting (administering) milk protein solutions of various concentrations.
- FIG. 2 shows changes in FSR with swimming exercise.
- FIG. 3 shows the blood 3MeHis concentration when each concentration of milk protein solution was orally ingested (administered).
- the muscle synthesis promoter of the present invention is a muscle synthesis promoter for a subject in need of immediate protein absorption, comprising a milk protein mixture containing casein protein and whey protein as an active ingredient. It is a muscle synthesis promoter having a protein amount ratio (casein protein / whey protein) of 2 to 20 to the casein protein.
- the active ingredient means an ingredient required for exerting an effect of promoting muscle synthesis for a subject requiring immediate absorption of protein.
- Subjects requiring immediate absorption of protein means subjects who need to promote muscle protein synthesis in order to repair muscle tissue and promote muscle growth, such as health promotion and exercise capacity
- the exercise is preferably strength training (resistance exercise), more preferably long-term strength training, for example, continuous, in that muscle synthesis is promoted by applying a certain load to the strength.
- the strength training is continued for 30 minutes to 5 hours at a frequency of 1 to 7 days in a week.
- Examples of strength training include dumbbell exercise, squat exercise, and machine training.
- Examples of subjects who take the muscle synthesis promoter of the present invention include, for example, athletes, sports enthusiasts (athletes), those who need exercise to improve lifestyle-related diseases, and elderly people for health promotion. Examples include those who require exercise, or patients who suffer from a muscle injury disease (eg, sarcopenia) and who need to promote muscle synthesis through exercise. Further, the target may be an animal other than a human (domestic animals such as horses and cows, pets such as dogs and cats, appreciation animals kept in zoos, etc.).
- the time when the muscle synthesis promoter of the present invention is ingested (administered) to a subject in need of immediate protein absorption may be before exercise, after exercise, or during exercise.
- the time of intake is preferably after exercise, more preferably immediately after exercise.
- the intake period is preferably within 3 hours after the end of exercise, immediately after exercise. More preferably, within 2 hours after the end of exercise, more preferably within 1 hour after the end of exercise, and particularly preferably within 30 minutes after the end of exercise (Levenhagenhaet al. Am J physiol Endocrinol Metab (2001), 280, E982-E993).
- Immediately effective muscle synthesis promoting effect equivalent to whey protein is the same level of protein absorption rate and absorption as observed when orally ingesting (administering) a protein mainly composed of whey protein. It means the same level of action as the accompanying muscle synthesis promoting action.
- the muscle synthesis promoting action includes an anabolic action of muscle protein from amino acids.
- the muscle synthesis promoting action can be confirmed, for example, by measuring the triceps surae muscle synthesis rate (FSR) of the upper limb in the test group within 1 hour after administration of the test substance after the rat swimming test. it can.
- FSR triceps surae muscle synthesis rate
- the muscle synthesis promoting action includes a muscle protein degradation inhibiting action, that is, a catabolic preventing action from muscle protein to amino acid.
- the degradation inhibitory action of muscle protein can be confirmed by measuring the concentration of 3 methylhistidine within 1 hour after administration of the test substance after, for example, a rat swimming test (Example 1). (See (3)).
- Protein amount means the amount of protein as a polymer of amino acids contained in various proteins such as milk protein, whey protein or casein protein.
- Protein amount ratio means the ratio of the amount of protein as a polymer of amino acids contained in various proteins such as milk protein, whey protein, or casein protein.
- the amount of protein may be calculated based on known information such as a food composition table, or may be calculated by measuring by a conventional method such as Kjeldahl method or Raleigh method. Actually, in the case of the Kjeldahl method, it can be calculated by measuring nitrogen contained in various proteins and multiplying the value by a nitrogen-protein conversion factor (usually 6.25).
- the milk protein mixture used in the present invention is not particularly limited as long as it contains whey protein and casein protein in a specific protein amount ratio, but the whey protein and casein protein separated and purified separately are not specifically limited. It may be prepared by mixing so as to obtain a protein amount ratio, or a raw material (material) or food and drink that already contains whey protein and casein protein that have not been separated or purified separately in a specific protein amount ratio You may mix and prepare goods. At this time, the milk protein mixture used in the present invention does not require a separation step or purification step of whey protein or casein protein, and the production cost thereof is low, so that whey protein and casein protein are already specified. Prepared by mixing the raw materials and foods and drinks that are contained in the protein content ratio as the main components, and mixing the whey protein and casein protein purified separately as needed to achieve a specific protein content ratio. Is preferred.
- whey protein separated and purified separately from casein protein examples include whey stock solutions (sweet whey, acid whey, etc.), concentrates, dried products (whey powder, etc.), frozen products, hydrolyzed products, etc. And reducing solutions thereof. Further, desalted whey, whey protein concentrate (WPC), purified whey protein (WPI), ⁇ -lactalbumin ( ⁇ -La), ⁇ -lactoglobulin ( ⁇ -Lg), immunoglobulin, lactoferrin, and the like, and These reducing solutions can be used.
- Casein protein separated and purified separately from whey protein includes, for example, casein isolate (natural cheese such as fresh cheese, sodium caseinate, calcium caseinate), its concentrate, its dried product, its A frozen material, a hydrolyzate thereof, a reducing solution thereof, and the like can be used. Furthermore, purified products such as ⁇ -casein, ⁇ -casein, and ⁇ -casein, and reducing solutions thereof can be used.
- raw materials and foods and beverages that already contain whey protein and casein protein in a specific protein ratio include, for example, raw milk, pasteurized milk (such as milk), skim milk, component-adjusted milk, processed milk, and dairy products ( Concentrated milk, powdered milk, condensed milk, fermented milk (yogurt, etc.), lactic acid bacteria beverages, processed cheeses, ice creams, creams), milk protein concentrate (MPC), its concentrate, its dried product, its frozen product, its Hydrolysates and the like, and reducing solutions thereof can be used.
- MPC milk protein concentrate
- the milk protein mixture used in the present invention is composed of whey protein and casein protein having a specific protein amount ratio.
- the protein amount ratio of casein protein to whey protein (casein protein / whey protein) is 2 to 20, preferably 2 to 10, more preferably 2 to 6, still more preferably 2 to 4, and particularly preferably 2 to 3.5.
- the protein ratio (casein protein / whey protein) between casein protein and whey protein is intentionally adjusted (designed), which is greatly different from the conventional technology. Yes.
- the muscle synthesis promoter of the present invention has high heat resistance (thermal stability) and exhibits a heat resistance effect.
- having a heat-resistant effect means that the protein does not solidify (aggregate) due to heat denaturation even when it is treated at a specific temperature. Specifically, it is a condition used in general processing of milk. This means that the protein is not heat denatured even if heat-sterilized by the method.
- the muscle synthesis promoter of the present invention has a heat resistance effect. More specifically, it is heat sterilized (LTLT treatment: low temperature and long time heating) at 62 to 65 ° C.
- the heat sterilization method includes a batch type in which the processing liquid is heated and held using a tank or the like, an indirect heating type using a plate type heat exchanger or a tube type heat exchanger, and a steam injection type heating device. And a known method such as a direct heating method using a steam infusion type heating device or a current heating method using a Joule heating device can be used.
- the milk protein mixture is ingested (administered) so that the total protein amount is 0.13 g / kg body weight or more per meal, Specifically, the weight is 0.13 to 0.7 g / kg body weight, preferably 0.13 to 0.6 g / kg body weight, more preferably 0.13 to 0.5 g / kg body weight, still more preferably 0.00. It is ingested (administered) so as to be 15 to 0.4 g / kg body weight, particularly preferably 0.2 to 0.4 g / kg body weight.
- the typical weight of the subject is estimated to be about 60 kg.
- one meal means one time in a state requiring immediate absorption of protein.
- a single meal is not taken at a time (at a time), but several times. May be taken separately.
- the amino acid concentration in the bloodstream can be increased immediately when it is ingested in several degrees. In this respect, it is preferably within 2 hours after the end of exercise, more preferably within 1 hour after the end of exercise, more preferably within 30 minutes after the end of exercise, and particularly preferably the end of exercise. Within 5 minutes later.
- the method for ingesting (administering) the muscle synthesis promoter of the present invention to a subject in need of immediate protein absorption can be appropriately selected from oral ingestion (oral administration), enteral administration, gastric fistula and the like depending on the subject and application. Although it can be selected, it is preferably taken orally.
- the muscle synthesis promoter of the present invention can take any form as long as the effect is exerted, and examples thereof include a solid form, a liquid form, a gel form, a paste form, and a paste form.
- a solid form among solids, it may be powder, granule, capsule, block, In view of good processability, it is preferably a liquid.
- a long-term storage period can be set in a refrigerated state and at room temperature.
- the water content can be appropriately adjusted. Specifically, it may be 10 to 95% by mass, preferably 20 to 95% by mass, and more preferably. Is 30 to 90% by mass, more preferably 40 to 90% by mass.
- the water content or solid content
- muscle synthesis can be effectively promoted.
- the muscle synthesis promoter of the present invention comprises a unit package form per serving, and the milk protein mixture is added to the total amount of food intake in the unit package form. It is desirable that the amount of protein is adjusted to 8 g or more, specifically, 8 to 40 g, preferably 8 to 20 g, more preferably 9 to 20 g, still more preferably 9 to 15 g, particularly preferably 10 to 15 g. It adjusts so that it may become.
- ⁇ consisting of a unit packaging form per meal '' is a form in which the intake amount per meal is determined in advance, for example, as a food and drink that can be taken orally in a specific amount, not only general foods, It means forms such as beverages (drinks, etc.), health supplements, health functional foods, and supplements.
- unit packaging form per meal for example, in the case of liquid beverages, gel-like, paste-like, paste-like jelly, powder-like, granule-like, capsule-like, block-like solid foods, etc.
- a specific amount (dose) can be defined in packaging containers such as cans, glass bottles (such as bottles), plastic containers (such as plastic bottles), packs, pouches, film containers, paper boxes, etc., or intake per serving (usage, dose) ) Is displayed on a packaging container, a homepage, etc., and the form which can prescribe
- packaging containers such as cans, glass bottles (such as bottles), plastic containers (such as plastic bottles), packs, pouches, film containers, paper boxes, etc., or intake per serving (usage, dose) ) Is displayed on a packaging container, a homepage, etc., and the form which can prescribe
- the form of the muscle synthesis promoter of the present invention is a so-called health drink
- 8 to 40 g of the beverage in which the milk protein is suspended or dissolved is provided.
- the capacity (dose) of a single drink per meal is adjusted by the amount of water so that it is 100 to 1000 ml, and is placed in a packaging container such as a metal can, a glass bottle (such as a bottle), or a plastic container (such as a plastic bottle). (Filled) form.
- 8 to 40 g of the above-described milk protein suspension or dissolved beverage is displayed on a packaging container or homepage as the amount of intake (usage, dose) (for example, 100 to 1000 ml) per serving, and several servings (several (Batch) is a collective capacity, and is a form that is put (filled) in a large-capacity packaging container or the like.
- the muscle synthesis promoter of the present invention is manufactured so as to contain a predetermined milk protein mixture
- its manufacturing process is not limited.
- the muscle synthesis promoter of the present invention includes various components such as milk protein and milk fat with respect to raw milk (raw milk), sterilized milk, concentrated milk, powdered milk, and reduced milk according to a known manufacturing method (manufacturing method). It can be manufactured by blending (adjusting) the ingredients, or various ingredients such as milk protein and milk fat can be blended (adjusted) with component-adjusted milk and processed milk (such as low-fat milk and non-fat milk). ) Can also be manufactured.
- the muscle synthesis promoter of the present invention can provide a composition comprising a muscle synthesis promoter. That is, the muscle synthesis promoter of the present invention can be used alone as it is, but as long as the muscle synthesis promotion function is exhibited, various compositions for oral intake (for oral administration) such as foods and drinks and pharmaceuticals. A composition (for example, a pharmaceutical composition or a food / beverage product composition) having an immediate effect of promoting muscle synthesis can also be obtained. Therefore, according to one embodiment of the present invention, a composition comprising the muscle synthesis promoter of the present invention is provided.
- Food and drink is something other than a pharmaceutical product (pharmaceutical composition), as long as it can be taken orally, such as a solution, suspension, emulsion, powder, solid molded product, etc.
- a pharmaceutical product pharmaceutical composition
- Well not particularly limited.
- food and drink include instant noodles, retort food, canned food, microwave food, instant soup and miso soup, freeze-dried food, etc .; soft drinks, fruit juice drinks, vegetable drinks, soy milk drinks, coffee Beverages such as beverages, tea beverages, powdered beverages, concentrated beverages, alcoholic beverages; flour products such as bread, pasta, noodles, cake mixes, bread crumbs; strawberries, caramel, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks , Crackers, Japanese confectionery, dessert confectionery, etc .; sauces, tomato processing seasonings, flavor seasonings, cooking mixes, sauces, dressings, soups, curry and stew ingredients; processed oils and fats, butter Oils and fats such as margarine and mayonnaise; milk drinks, fermented milk (yogurt, etc.), lactic acid bacteria drinks, natural tea 'S, process cheese, ice cream, dairy products such as cream; agricultural canning, jam, marmalade such, processed agricultural products such as serial; such as frozen food, and the like.
- Foods and drinks include health foods, functional foods, dietary supplements, foods for specified health use, foods for the sick, infant formula, powdered milk for pregnant or lactating women, or rapid muscle synthesis.
- subjected the indication that it is a thing used for promotion is also included.
- “Pharmaceuticals” are those prepared as oral preparations or parenteral preparations in accordance with conventional methods, using additives that are acceptable for formulation.
- the pharmaceutical is an oral preparation, it should be in the form of a solid preparation such as a tablet, powder, fine granule, granule, capsule, pill or sustained release, or a liquid preparation such as a solution, suspension or emulsion. Can take.
- a pharmaceutical is a parenteral formulation, it can take the form of an injection or a suppository. In terms of ease of ingestion (administration) to a patient, the pharmaceutical is preferably an oral preparation.
- additives that are acceptable for formulation include, for example, excipients, stabilizers, preservatives, wetting agents, emulsifiers, lubricants, sweeteners, coloring agents, fragrances, buffers, antioxidants. Agents, pH adjusters and the like.
- the muscle synthesis promoter of the present invention has a heat resistance effect. Therefore, in the composition in which the muscle synthesis promoter of the present invention is blended (added, mixed), the muscle synthesis promoter of the present invention has a heat-resistant effect, so that it can be preferably provided as a liquid product form. It can be provided as a product form for warm sales using a hot vendor or the like.
- composition of the muscle synthesis promoter of the present invention may be in any form as long as the effect is exerted, for example, solid, liquid, gel, Examples include pasty and pasty forms.
- the composition containing the muscle synthesis promoter of the present invention may be in the form of a solid, powder, granule, capsule, or block. However, it is preferably a liquid in terms of good processability.
- the present invention is a food / beverage product obtained by blending (adding, mixing) and heat-sterilizing the muscle synthesis promoter of the present invention, comprising a unit packaging form per serving, and the unit packaging form Among them, it is desirable that the milk protein mixture is adjusted to a total protein amount of 8 to 40 g as a single meal intake, preferably 8 to 20 g, more preferably 9 to 20 g, still more preferably 9 to 15 g, particularly preferably.
- Food / beverage products and methods for producing the same are provided, which are provided with an effect of promoting muscle synthesis by immediate absorption of protein, adjusted to 10 to 15 g.
- the operation (process) of “mixing (addition, mixing) and heat sterilization” to a predetermined component is not particularly limited as long as the operation is finally adjusted to a predetermined component and sterilized. Operation that mixes all necessary components and adjusts them to the prescribed components and then heat sterilizes them together, or operation that sterilizes the necessary individual components separately and mixes them to adjust them to the prescribed components Etc. Therefore, in the present invention, the order and number of times of this blending (addition, mixing) and heat sterilization are arbitrary.
- the food / beverage product (the food / beverage product of the present invention) is preferably a food / beverage product packed in a packaging container, and more preferably a food / beverage product packed in a packaging container for heat sale. That is, since the food and drink have heat resistance, the protein will not be extremely denatured even if it is heated and sold. Therefore, in the food and drink composed only of the conventional whey protein or the whey protein as a main component, as a warm food and drink, it could not be provided outdoors in winter, etc., whereas in the food and drink, as a warm food and drink, It can be provided outdoors in winter (especially in cold conditions) and can be consumed (drinked) by consumers.
- the practical use of the food-drinks with the effect of accelerating muscle synthesis corresponding to new needs can be expected.
- a hot sale beverage or a hot sale food stored in a hot vendor or hot water for example, a hot sale beverage or a hot sale food stored in a hot vendor or hot water, and a necessary amount are put in a cooking utensil.
- heated beverages and heated foods heated by gas stoves, electric heating stoves, microwaves, and the like can be mentioned.
- warm sales it is generally stored at around 30-80 ° C or around 50-80 ° C.
- the food or drink is a milk drink.
- milk beverage means a beverage containing milk solids (a combination of nonfat milk solids and milk fat) at 3.0% by weight or more.
- vitamins, minerals, oligosaccharides, lactose, fruit juice and the like can be blended in the milk beverage.
- the production process is not limited as long as the food or drink is produced so as to contain a predetermined milk protein mixture (at a predetermined concentration). It can manufacture based on manufacturing processes, such as adjusted milk, processed milk, and a milk drink.
- the food / beverage products of this invention mix
- a packaged container-packed milk beverage that is preferably adjusted to 0.5 to 4 g / 200 ml, particularly preferably 0.5 to 3
- a milk protein mixture comprising casein protein and whey protein, wherein the protein amount ratio of casein protein to whey protein (casein protein / whey protein) is 2 to 20,
- a method for producing a packaged-packed milk beverage comprising a step of adding to one or more selected from the group consisting of raw milk, pasteurized milk, concentrated milk, powdered milk and reduced milk, and a heat sterilization step, wherein the milk protein
- the total protein amount of the mixture is adjusted to 8 g / 200 ml, preferably 8 to 20 g / 200 ml, more preferably 9 to 20 g / 200 ml, still more preferably 9 to 15 g / 200 ml, particularly preferably 10 to 15 g / 200 ml
- Milk fat content is 8g or less / 200ml, preferably 0.1-8g 200 ml, more preferably 0.1 to 6 g / 200 ml, further preferably 0.5 to 4 g / 200 ml,
- “Reduced milk” means liquid milk prepared by dispersing and dissolving milk raw materials such as powdered milk and concentrated milk in water.
- milk raw material include whole milk powder, skim milk powder, whole fat concentrated milk, nonfat concentrated milk, butter, cream, and unfinished milk.
- aggregation due to heat denaturation of the whey protein is not observed (see Example 2), and therefore, the immediate protein absorption effect is maintained as in the muscle synthesis promoter of the present invention.
- a milk protein mixture comprising casein protein and whey protein, wherein the protein content ratio of casein protein to whey protein (casein protein / whey protein) is 2 to 20,
- a method of promoting muscle synthesis comprising ingesting a subject in need of absorption.
- a milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is instantly absorbed by the protein.
- a method for promoting muscle synthesis comprising ingesting a subject in need thereof.
- the “medical action for humans” means an action that requires a doctor or the like to ingest (administer) a medicine to a human.
- the muscle synthesis promoting method of the present invention can be carried out according to the contents described in the present specification for the muscle synthesis promoting agent of the present invention.
- the milk protein mixture is ingested (administered) so that the total protein amount is 0.13 g / kg body weight or more per meal.
- the weight is 0.13-0.7 g / kg body weight, preferably 0.13-0.6 g / kg body weight, more preferably 0.13-0.5 g / kg body weight, still more preferably It can be ingested so as to be 0.15 to 0.4 g / kg body weight, particularly preferably 0.2 to 0.4 g / kg body weight.
- the milk protein mixture in the method for promoting muscle synthesis of the present invention, can be ingested so that the total protein amount is 8 g or more per serving. It can be ingested so as to be ⁇ 40 g, preferably 8 to 20 g, more preferably 9 to 20 g, still more preferably 9 to 15 g, particularly preferably 10 to 15 g.
- the milk protein mixture in the muscle synthesis promotion method of the present invention, can be ingested in a heated liquid form to a subject that needs immediate absorption of the protein.
- a muscle synthesis promoting agent comprising a milk protein mixture comprising casein protein and whey protein for promoting muscle synthesis of a subject in need of immediate protein absorption.
- a muscle synthesis promoter having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is provided.
- the use of the muscle synthesis promoter of the present invention can be carried out according to the contents described herein for the muscle synthesis promoter of the present invention.
- a milk protein mixture comprising casein protein and whey protein for the manufacture of a food or beverage or pharmaceutical product for promoting muscle synthesis in a subject in need of immediate protein absorption.
- a muscle synthesis promoter comprising a muscle synthesis promoter having a protein content ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is provided.
- the use of the muscle synthesis promoter of the present invention can be carried out according to the contents described herein for the muscle synthesis promoter of the present invention.
- muscle synthesis promoting effect muscle synthesis promoting effect
- body water retention action body water retention effect
- Example 1 Muscle synthesis promoting action by milk protein mixture
- Rat swimming test SD male rats obtained from CLEA Japan, Inc. having an initial weight of 140 to 160 g were used as experimental animals. Rats were divided into 6 groups of 9 to 10 animals so that there was no difference in body weight between test groups (groups). All rats were individually housed in stainless steel cages at room temperature of 22 ⁇ 2 ° C. with a light period of 7 to 19 o'clock and a dark period of 19 to 7 o'clock.
- rats were preliminarily raised for 3 to 4 days, and the rats were subjected to a swimming test according to the following protocol (the rats were exercised).
- Rat swimming test (exercise) protocol Day 1: Rats were subjected to 2 hours of swimming exercise, 45 minutes of rest, 2 hours of swimming exercise for a total of 4 hours of swimming without weight load. The diet after exercise (solid feed MF) was freely taken. Day 2: The rats were subjected to 3 hours of swimming exercise, 45 minutes of rest, 3 hours of swimming exercise for a total of 6 hours without weight load. The diet after exercise (solid feed MF) was freely taken. Day 3: Rats were subjected to a total of 6 hours of swimming exercise without weight load, 3 hours of swimming exercise, 45 minutes of rest, 3 hours of swimming exercise. As a diet after exercise, 5 g of a restricted diet (powder feed MF) was ingested.
- a restricted diet porice feed MF
- the rats were subjected to a 2-hour swimming exercise without weight load.
- a milk beverage (milk protein solution) was prepared using milk protein and milliQ water so that the protein concentrations shown in Table 1 were obtained.
- the rats were orally ingested milk drink and milliQ water at 24.24 ml / kg BW (test group 1-5 and comparative group 1).
- the milk protein includes milk protein concentrate (MPC480, manufactured by Fontera, milk protein 77.2% by weight, milk fat content 1.2% by weight, lactose 9.2% by weight, ash content 7.1% by weight, Water (5.3 wt%) was used.
- This MPC480 is a mixture of casein protein and whey protein obtained by subjecting skim milk to membrane separation treatment (UF treatment, MF treatment, etc.), removing lactose and ash, and concentrating mainly on casein protein and whey protein.
- the form is a dry powder.
- apparatus LC / MS / MS (manufactured by Waters), column: ACQUITY UPLC BEH C18 (manufactured by Waters), mobile phase: 0.05% TFA water / 0.05% TFA-containing acetonitrile, injection volume 3 ⁇ l, flow rate 0.3 ml / min, UV 215 nm.
- FSR skeletal muscle synthesis rate
- the obtained numerical values were statistically processed to obtain an average value ⁇ standard error. Specifically, a one-way analysis of variance was performed, followed by Tukey's multiple comparison test. The significance level was less than 5% (p ⁇ 0.05). The result is shown in FIG. When there was a significant difference in the figure, different characters were attached. For example, it is shown that there is a significant difference between a group with a (comparison group 1 or the like) and a group with b (test group 3) or a group with c (test group 4 or the like). ing. Further, for example, it is shown that there is no significant difference between a group to which a (comparison group 1 or the like) or b (test group 3) is attached and a group to which ab is attached (test group 2).
- the obtained numerical values were statistically processed to obtain an average value ⁇ standard error. Specifically, a one-way analysis of variance was performed, followed by Tukey's multiple comparison test. The significance level was less than 5%. The result is shown in FIG. When there was a significant difference in the figure, different characters were attached.
- Example 2 Muscle synthesis promoting action by milk beverage containing milk protein (1) Preparation (production) of milk beverage containing milk protein Raw milk (milk protein 3.3 wt%, milk fat 3.8 wt%, lactose 4.8 wt%, ash 0.7 wt%, moisture 87.4 wt%, obtained from Meiji Co., Ltd.) Protein was added and mixed to prepare raw milk so that the milk protein concentration shown in Table 2 was obtained. And according to the usual method for producing milk, the indirect heating method using a plate heat exchanger is sterilized by heating at 130 ° C. for 2 seconds, and then cooled to 10 ° C. or lower, so that the milk protein has a high concentration. (Milk test solution 6 and 7) was obtained.
- Raw milk milk protein 3.3 wt%, milk fat 3.8 wt%, lactose 4.8 wt%, ash 0.7 wt%, moisture 87.4 wt%, obtained from Meiji Co., Ltd.
- the milk protein added to the milk beverage includes milk protein concentrate (MPC480, manufactured by Fontera, milk protein 77.2% by weight, milk fat content 1.2% by weight, lactose 9.2% by weight, ash content 7 0.1 wt%, water 5.3 wt%).
- MPC480 is a mixture of casein protein and whey protein obtained by subjecting skim milk to membrane separation treatment (UF treatment, MF treatment, etc.), removing lactose and ash, and concentrating mainly on casein protein and whey protein.
- the form is a dry powder.
- FSR skeletal muscle synthesis rate
- test sections 6 and 7 were as high as 6.7% / day and 7.7% / day, respectively.
- the FSR is 8.8% / day when whey protein is taken orally at 3.11 g / kg BW after 2 hours of treadmill exercise as a protein amount. , J. Nutr. 137, 357-362 (2007)).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Provided is a muscle repair promoter intended for use in a target of which rapid absorption of protein is required, and containing as an effective ingredient a lactoprotein mixture that includes casein protein and whey protein, wherein the muscle repair promoter has a protein ratio of casein protein to whey protein (casein protein/whey protein) of 2-20. The muscle repair promoter exhibits rapid muscle repair promoting action equivalent to that of whey protein.
Description
本特許出願は、先に出願された日本国特許出願である特願2013―189703(出願日:2013年9月12日)に基づく優先権の主張を伴うものである。この先の特許出願における全開示内容は、引用することにより本願発明の開示の一部とされる。
This patent application is accompanied by a claim of priority based on Japanese Patent Application No. 2013-189703 (application date: September 12, 2013), which was a previously filed Japanese patent application. The entire disclosure of this earlier patent application is incorporated herein by reference.
技術分野
本発明は、タンパク質の即時吸収を必要とする対象のための筋肉合成促進剤に関する。 TECHNICAL FIELD The present invention relates to muscle synthesis promoters for subjects in need of immediate protein absorption.
本発明は、タンパク質の即時吸収を必要とする対象のための筋肉合成促進剤に関する。 TECHNICAL FIELD The present invention relates to muscle synthesis promoters for subjects in need of immediate protein absorption.
背景技術
近年、健康増進や運動能力向上を目的として、筋肉合成の促進、筋肉喪失の予防、および筋肉量の回復促進のために、タンパク質を主成分とする栄養補助剤(サプリメント)を経口摂取して、運動する者(対象)は多い。このような栄養補助剤として、プロテイン粉末があり、その主成分として、牛乳を原料とするホエイタンパク質(乳清タンパク質)およびカゼインタンパク質が知られている。 Background Art In recent years, for the purpose of promoting health and improving exercise capacity, orally ingesting dietary supplements (protein supplements) based on protein to promote muscle synthesis, prevent muscle loss, and promote muscle mass recovery. Many people (subjects) exercise. As such a nutritional supplement, there is protein powder, and as its main component, whey protein (whey protein) and casein protein made from milk are known.
近年、健康増進や運動能力向上を目的として、筋肉合成の促進、筋肉喪失の予防、および筋肉量の回復促進のために、タンパク質を主成分とする栄養補助剤(サプリメント)を経口摂取して、運動する者(対象)は多い。このような栄養補助剤として、プロテイン粉末があり、その主成分として、牛乳を原料とするホエイタンパク質(乳清タンパク質)およびカゼインタンパク質が知られている。 Background Art In recent years, for the purpose of promoting health and improving exercise capacity, orally ingesting dietary supplements (protein supplements) based on protein to promote muscle synthesis, prevent muscle loss, and promote muscle mass recovery. Many people (subjects) exercise. As such a nutritional supplement, there is protein powder, and as its main component, whey protein (whey protein) and casein protein made from milk are known.
ホエイタンパク質では、経口摂取から消化吸収までの速度(吸収速度)が速く(時間が短く)、また、BCAA(分岐鎖アミノ酸:バリン、ロイシン、イソロイシン)が多く含まれるため、筋肉疲労を防ぎながら、筋肉を効率良く増強できるといわれている。一方、カゼインタンパク質では、ホエイタンパク質と比べて、ゆっくりと持続的に代謝されるため、経口摂取から消化吸収までの速度(吸収速度)が遅く(時間が長く)、即時吸収を必要とする対象には不向きであるといわれている(特許文献1参照)。そのため、プロテイン粉末には、ホエイタンパク質が主に用いられている。
Whey protein has a high rate (absorption time) from ingestion to digestion and absorption (short time) and contains a lot of BCAA (branched chain amino acids: valine, leucine, isoleucine), thus preventing muscle fatigue, It is said that muscles can be strengthened efficiently. On the other hand, casein protein is slowly and continuously metabolized compared to whey protein, so the rate from oral ingestion to digestion absorption (absorption rate) is slow (longer time) and needs immediate absorption. Is said to be unsuitable (see Patent Document 1). Therefore, whey protein is mainly used as protein powder.
このような吸収速度の差を利用して、吸収の速いホエイタンパク質と、持続的に吸収されるカゼインタンパク質とを1:1で混合した、混合プロテインも開発されている(例えば、DNSプロテインスローローディング)。
Utilizing such a difference in absorption rate, a mixed protein in which whey protein having high absorption and casein protein to be continuously absorbed are mixed at 1: 1 has been developed (for example, DNS protein slow loading). ).
しかしながら、ホエイタンパク質では、耐熱性(熱安定性)が低いため、熱変性を起こし、加熱に伴う凝集が起こりやすい。実際に、プロテイン粉末では、水に溶解して摂取する以外の摂取方法は推奨されていない。したがって、プロテイン粉末では、粉っぽさが残り、嗜好性の高いものとはいえなかった。さらに、過剰に加熱した場合には、ホエイタンパク質が熱変性により固まり、吸収効率が低下するという問題があった。
However, since whey protein has low heat resistance (thermal stability), it undergoes thermal denaturation and tends to aggregate due to heating. In fact, protein powders are not recommended for consumption other than being dissolved in water. Therefore, protein powder remains powdery and cannot be said to have high palatability. Furthermore, when heated excessively, the whey protein is hardened by heat denaturation and there is a problem that the absorption efficiency is lowered.
このように、ホエイタンパク質と同等の即効的な筋肉合成促進効果を奏しながら、耐熱性が高く、加工適性が良好な素材や組成物は、これまで知れられていなかった。
Thus, materials and compositions having high heat resistance and good processing suitability while exhibiting an immediate muscle synthesis promoting effect equivalent to whey protein have not been known so far.
本発明者らは今般、従来技術では、タンパク質の吸収速度が遅くホエイタンパク質のような即効性の効果がないといわれてきたカゼインタンパク質により、ホエイタンパク質の大半を代替した乳タンパク質混合物であっても、ホエイタンパク質と同等の即効的な筋肉合成促進作用があるという現象を予想外にも見出した。約80%のカゼインタンパク質と約20%のホエイタンパク質とからなる乳タンパク質は、カゼインタンパク質単独と同様の吸収性を有するものとして一般に知られていた(Judy A. Driskell, "Sports Nutrition Fats and proteins" CRC Press, p149, 2007年参照)ため、上記の現象は驚くべきものであった。また、この乳タンパク質混合物では、ホエイタンパク質を単独で用いるよりも、耐熱性が高く、加工適性が良好であることを見出した。本発明は、これらの知見に基づくものである。
In the prior art, the present inventors have now proposed a milk protein mixture in which the majority of whey protein is replaced by casein protein, which has been said to have a slow protein absorption rate and no immediate effect like whey protein. Unexpectedly, it was found that there is an immediate effect of promoting muscle synthesis equivalent to whey protein. Milk protein consisting of about 80% casein protein and about 20% whey protein was generally known to have the same absorbency as casein protein alone (Judy A. Driskell, "Sports Nutrition Fats and proteins" Therefore, the above phenomenon was surprising. It was also found that this milk protein mixture has higher heat resistance and better processability than using whey protein alone. The present invention is based on these findings.
すなわち、本発明は、ホエイタンパク質と同等の即効的な筋肉合成促進作用を有する筋肉合成(増強)促進剤を提供することをその目的とする。
That is, an object of the present invention is to provide a muscle synthesis (enhancement) promoter having an immediate effect of promoting muscle synthesis equivalent to that of whey protein.
本発明によれば、以下の発明が提供される。
(1)カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を有効成分として含んでなる、タンパク質の即時吸収を必要とする対象のための筋肉合成促進剤であって、ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である筋肉合成促進剤。
(2)前記乳タンパク質混合物が総タンパク質量で一食あたり0.13~0.7g/kg体重となるように摂取される、上記(1)に記載の筋肉合成促進剤。
(3)一食あたりの単位包装形態からなり、該単位包装形態中に、前記乳タンパク質混合物を一食摂取量として総タンパク質量で8~40gに調整してなる、上記(1)または(2)に記載の筋肉合成促進剤。
(4)タンパク質の即時吸収を必要とする対象が、運動する対象である、上記(1)~(3)のいずれかに記載の筋肉合成促進剤。
(5)運動が筋肉トレーニングである、上記(4)に記載の筋肉合成促進剤。
(6)液状形態である、上記(1)~(5)のいずれかに記載の筋肉合成促進剤。
(7)上記(1)~(6)のいずれかに記載の筋肉合成促進剤を配合および加熱殺菌してなる飲食品であって、一食あたりの単位包装形態からなり、該単位包装形態中に、前記乳タンパク質混合物を一食摂取量として総タンパク質量で8~40gに調整してなる、タンパク質の即時吸収による筋肉合成促進作用が付与された、包装容器詰の飲食品。
(8)ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、生乳、殺菌乳、濃縮乳、粉乳および還元乳からなる群から選択される一種以上と混合および加熱殺菌してなる乳飲料であって、前記乳タンパク質混合物を総タンパク質量で8g以上/200mlおよび乳脂肪量を8g以下/200mlに調整してなる、タンパク質の即時吸収による筋肉合成促進作用が付与された、包装容器詰の乳飲料。
(9)ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、生乳、殺菌乳、濃縮乳、粉乳および還元乳からなる群から選択される一種以上に添加する工程、および加熱殺菌する工程を含んでなる、包装容器詰の乳飲料の製造方法であって、前記乳タンパク質混合物を総タンパク質量で8g以上/200mlおよび乳脂肪量を8g以下/200mlに調整してなる、タンパク質の即時吸収による筋肉合成促進作用が付与された、包装容器詰の乳飲料の製造方法。
(10)ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、タンパク質の即時吸収を必要とする対象に摂取させることを含んでなる、筋肉合成促進方法(ヒトに対する医療行為を除く)。
(11)ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、タンパク質の即時吸収を必要とする対象に摂取させることを含んでなる、筋肉合成促進方法。
(12)前記乳タンパク質混合物を総タンパク質量で一食あたり0.13~0.7g/kg体重となるように摂取させる、上記(10)または(11)に記載の筋肉合成促進方法。
(13)前記乳タンパク質混合物を、乳タンパク質混合物の総タンパク質量で一食あたり8~40gとなるように摂取させる、上記(12)に記載の筋肉合成促進方法。
(14)前記乳タンパク質混合物を、タンパク質の即時吸収を必要する対象に加温液状形態で摂取させることを含んでなる、上記(10)~(13)のいずれかに記載の筋肉合成促進方法。
(15)タンパク質の即時吸収を必要とする対象が運動する対象である、上記(10)~(14)のいずれかに記載の筋肉合成促進方法。
(16)運動する対象が運動直後の対象である、上記(15)に記載の筋肉合成促進方法。
(17)運動が筋肉トレーニングである、上記(15)または(16)に記載の筋肉合成促進方法。 According to the present invention, the following inventions are provided.
(1) A muscle synthesis promoter for a subject in need of immediate protein absorption, comprising a milk protein mixture containing casein protein and whey protein as an active ingredient, and the amount of casein protein relative to whey protein A muscle synthesis promoter having a ratio (casein protein / whey protein) of 2 to 20.
(2) The muscle synthesis promoter according to (1) above, wherein the milk protein mixture is taken so that the total protein amount is 0.13 to 0.7 g / kg body weight per serving.
(3) The above-mentioned (1) or (2), comprising a unit packaging form per serving, wherein the milk protein mixture is adjusted to 8 to 40 g in terms of the total protein amount as a meal intake. The muscle synthesis promoter described in 1.
(4) The muscle synthesis promoter according to any one of (1) to (3) above, wherein the subject in need of immediate protein absorption is a subject to exercise.
(5) The muscle synthesis promoter according to (4) above, wherein the exercise is muscle training.
(6) The muscle synthesis promoter according to any one of (1) to (5), which is in a liquid form.
(7) A food / beverage product obtained by blending and heat-sterilizing the muscle synthesis promoter according to any one of (1) to (6) above, comprising a unit packaging form per serving, and in the unit packaging form A food and drink packaged in a packaging container, provided with an effect of promoting muscle synthesis by immediate absorption of protein, wherein the milk protein mixture is adjusted to 8 to 40 g in terms of the total amount of protein as a single meal intake.
(8) A milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20, raw milk, pasteurized milk, concentrated milk, milk powder and reduced milk A milk beverage mixed and heat sterilized with at least one selected from the group consisting of milk, wherein the milk protein mixture is adjusted to a total protein content of 8 g / 200 ml and a milk fat content of 8 g / 200 ml A packaged container-packed milk drink that is provided with an action for promoting muscle synthesis by immediate protein absorption.
(9) A milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20, raw milk, pasteurized milk, concentrated milk, milk powder and reduced milk A method for producing a packaged-packed milk beverage comprising a step of adding to one or more selected from the group consisting of milk and a step of heat sterilization, wherein the milk protein mixture is 8 g / A method for producing a packaged-packed milk drink, which is provided with an effect of promoting muscle synthesis by immediate absorption of protein, wherein 200 ml and the amount of milk fat are adjusted to 8 g / 200 ml or less.
(10) A milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is taken by a subject who needs immediate absorption of the protein A method of promoting muscle synthesis, comprising:
(11) A milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is taken by a subject who needs immediate absorption of the protein. A method for promoting muscle synthesis, comprising:
(12) The method for promoting muscle synthesis according to (10) or (11) above, wherein the milk protein mixture is ingested so that the total protein amount is 0.13 to 0.7 g / kg body weight per serving.
(13) The method for promoting muscle synthesis according to (12), wherein the milk protein mixture is ingested so that the total protein amount of the milk protein mixture is 8 to 40 g per serving.
(14) The method for promoting muscle synthesis according to any one of the above (10) to (13), comprising ingesting the milk protein mixture in a heated liquid form to a subject in need of immediate absorption of the protein.
(15) The method for promoting muscle synthesis according to any one of (10) to (14) above, wherein the subject in need of immediate protein absorption is a subject to exercise.
(16) The method for promoting muscle synthesis according to (15), wherein the object to be exercised is an object immediately after exercise.
(17) The method for promoting muscle synthesis according to (15) or (16) above, wherein the exercise is muscle training.
(1)カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を有効成分として含んでなる、タンパク質の即時吸収を必要とする対象のための筋肉合成促進剤であって、ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である筋肉合成促進剤。
(2)前記乳タンパク質混合物が総タンパク質量で一食あたり0.13~0.7g/kg体重となるように摂取される、上記(1)に記載の筋肉合成促進剤。
(3)一食あたりの単位包装形態からなり、該単位包装形態中に、前記乳タンパク質混合物を一食摂取量として総タンパク質量で8~40gに調整してなる、上記(1)または(2)に記載の筋肉合成促進剤。
(4)タンパク質の即時吸収を必要とする対象が、運動する対象である、上記(1)~(3)のいずれかに記載の筋肉合成促進剤。
(5)運動が筋肉トレーニングである、上記(4)に記載の筋肉合成促進剤。
(6)液状形態である、上記(1)~(5)のいずれかに記載の筋肉合成促進剤。
(7)上記(1)~(6)のいずれかに記載の筋肉合成促進剤を配合および加熱殺菌してなる飲食品であって、一食あたりの単位包装形態からなり、該単位包装形態中に、前記乳タンパク質混合物を一食摂取量として総タンパク質量で8~40gに調整してなる、タンパク質の即時吸収による筋肉合成促進作用が付与された、包装容器詰の飲食品。
(8)ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、生乳、殺菌乳、濃縮乳、粉乳および還元乳からなる群から選択される一種以上と混合および加熱殺菌してなる乳飲料であって、前記乳タンパク質混合物を総タンパク質量で8g以上/200mlおよび乳脂肪量を8g以下/200mlに調整してなる、タンパク質の即時吸収による筋肉合成促進作用が付与された、包装容器詰の乳飲料。
(9)ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、生乳、殺菌乳、濃縮乳、粉乳および還元乳からなる群から選択される一種以上に添加する工程、および加熱殺菌する工程を含んでなる、包装容器詰の乳飲料の製造方法であって、前記乳タンパク質混合物を総タンパク質量で8g以上/200mlおよび乳脂肪量を8g以下/200mlに調整してなる、タンパク質の即時吸収による筋肉合成促進作用が付与された、包装容器詰の乳飲料の製造方法。
(10)ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、タンパク質の即時吸収を必要とする対象に摂取させることを含んでなる、筋肉合成促進方法(ヒトに対する医療行為を除く)。
(11)ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、タンパク質の即時吸収を必要とする対象に摂取させることを含んでなる、筋肉合成促進方法。
(12)前記乳タンパク質混合物を総タンパク質量で一食あたり0.13~0.7g/kg体重となるように摂取させる、上記(10)または(11)に記載の筋肉合成促進方法。
(13)前記乳タンパク質混合物を、乳タンパク質混合物の総タンパク質量で一食あたり8~40gとなるように摂取させる、上記(12)に記載の筋肉合成促進方法。
(14)前記乳タンパク質混合物を、タンパク質の即時吸収を必要する対象に加温液状形態で摂取させることを含んでなる、上記(10)~(13)のいずれかに記載の筋肉合成促進方法。
(15)タンパク質の即時吸収を必要とする対象が運動する対象である、上記(10)~(14)のいずれかに記載の筋肉合成促進方法。
(16)運動する対象が運動直後の対象である、上記(15)に記載の筋肉合成促進方法。
(17)運動が筋肉トレーニングである、上記(15)または(16)に記載の筋肉合成促進方法。 According to the present invention, the following inventions are provided.
(1) A muscle synthesis promoter for a subject in need of immediate protein absorption, comprising a milk protein mixture containing casein protein and whey protein as an active ingredient, and the amount of casein protein relative to whey protein A muscle synthesis promoter having a ratio (casein protein / whey protein) of 2 to 20.
(2) The muscle synthesis promoter according to (1) above, wherein the milk protein mixture is taken so that the total protein amount is 0.13 to 0.7 g / kg body weight per serving.
(3) The above-mentioned (1) or (2), comprising a unit packaging form per serving, wherein the milk protein mixture is adjusted to 8 to 40 g in terms of the total protein amount as a meal intake. The muscle synthesis promoter described in 1.
(4) The muscle synthesis promoter according to any one of (1) to (3) above, wherein the subject in need of immediate protein absorption is a subject to exercise.
(5) The muscle synthesis promoter according to (4) above, wherein the exercise is muscle training.
(6) The muscle synthesis promoter according to any one of (1) to (5), which is in a liquid form.
(7) A food / beverage product obtained by blending and heat-sterilizing the muscle synthesis promoter according to any one of (1) to (6) above, comprising a unit packaging form per serving, and in the unit packaging form A food and drink packaged in a packaging container, provided with an effect of promoting muscle synthesis by immediate absorption of protein, wherein the milk protein mixture is adjusted to 8 to 40 g in terms of the total amount of protein as a single meal intake.
(8) A milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20, raw milk, pasteurized milk, concentrated milk, milk powder and reduced milk A milk beverage mixed and heat sterilized with at least one selected from the group consisting of milk, wherein the milk protein mixture is adjusted to a total protein content of 8 g / 200 ml and a milk fat content of 8 g / 200 ml A packaged container-packed milk drink that is provided with an action for promoting muscle synthesis by immediate protein absorption.
(9) A milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20, raw milk, pasteurized milk, concentrated milk, milk powder and reduced milk A method for producing a packaged-packed milk beverage comprising a step of adding to one or more selected from the group consisting of milk and a step of heat sterilization, wherein the milk protein mixture is 8 g / A method for producing a packaged-packed milk drink, which is provided with an effect of promoting muscle synthesis by immediate absorption of protein, wherein 200 ml and the amount of milk fat are adjusted to 8 g / 200 ml or less.
(10) A milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is taken by a subject who needs immediate absorption of the protein A method of promoting muscle synthesis, comprising:
(11) A milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is taken by a subject who needs immediate absorption of the protein. A method for promoting muscle synthesis, comprising:
(12) The method for promoting muscle synthesis according to (10) or (11) above, wherein the milk protein mixture is ingested so that the total protein amount is 0.13 to 0.7 g / kg body weight per serving.
(13) The method for promoting muscle synthesis according to (12), wherein the milk protein mixture is ingested so that the total protein amount of the milk protein mixture is 8 to 40 g per serving.
(14) The method for promoting muscle synthesis according to any one of the above (10) to (13), comprising ingesting the milk protein mixture in a heated liquid form to a subject in need of immediate absorption of the protein.
(15) The method for promoting muscle synthesis according to any one of (10) to (14) above, wherein the subject in need of immediate protein absorption is a subject to exercise.
(16) The method for promoting muscle synthesis according to (15), wherein the object to be exercised is an object immediately after exercise.
(17) The method for promoting muscle synthesis according to (15) or (16) above, wherein the exercise is muscle training.
本発明の筋肉合成促進剤は、ホエイタンパク質と同等の即効的な筋肉合成促進効果を奏するとともに、ホエイタンパク質を単独で用いるよりも、耐熱性が高く、加工適性が良好である。したがって、本発明の筋肉合成促進剤では、即効的な筋肉合成促進作用を期待できるとともに、商業的に大量生産できる安価な製品形態として提供できる点で有利である。
The muscle synthesis promoter of the present invention has an immediate effect of promoting muscle synthesis equivalent to that of whey protein, and has higher heat resistance and better processability than using whey protein alone. Therefore, the muscle synthesis promoter of the present invention is advantageous in that it can be expected to have an immediate effect of promoting muscle synthesis and can be provided as an inexpensive product form that can be mass-produced commercially.
本発明の筋肉合成促進剤は、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を有効成分として含んでなる、タンパク質の即時吸収を必要とする対象のための筋肉合成促進剤であって、ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である筋肉合成促進剤である。
The muscle synthesis promoter of the present invention is a muscle synthesis promoter for a subject in need of immediate protein absorption, comprising a milk protein mixture containing casein protein and whey protein as an active ingredient. It is a muscle synthesis promoter having a protein amount ratio (casein protein / whey protein) of 2 to 20 to the casein protein.
「有効成分」とは、タンパク質の即時吸収を必要とする対象のための筋肉合成促進効果を奏する上で必要とされる成分のことを意味する。
“The active ingredient” means an ingredient required for exerting an effect of promoting muscle synthesis for a subject requiring immediate absorption of protein.
「タンパク質の即時吸収を必要とする対象」とは、筋肉組織を修復し、筋肉成長を助長するために、筋肉タンパク質の合成を促進する必要がある対象を意味し、例えば、健康増進や運動能力向上を目的として、筋肉合成の促進、筋肉喪失の予防、および筋肉量の回復促進のために、運動する対象を意味する。ここで、筋力に一定の負荷をかけることにより、筋肉合成が促進される点で、運動は、好ましくは、筋力トレーニング(レジスタンス運動)であり、より好ましくは、長期的な筋力トレーニング、例えば、連続して30分間~5時間を、1週間のうち1日~7日の頻度で継続される筋力トレーニングである。筋力トレーニングには、例えば、ダンベル運動、スクワット運動、マシントレーニングが挙げられる。
“Subjects requiring immediate absorption of protein” means subjects who need to promote muscle protein synthesis in order to repair muscle tissue and promote muscle growth, such as health promotion and exercise capacity For the purpose of improvement, it means a subject who exercises to promote muscle synthesis, prevent muscle loss, and promote muscle mass recovery. Here, the exercise is preferably strength training (resistance exercise), more preferably long-term strength training, for example, continuous, in that muscle synthesis is promoted by applying a certain load to the strength. Thus, the strength training is continued for 30 minutes to 5 hours at a frequency of 1 to 7 days in a week. Examples of strength training include dumbbell exercise, squat exercise, and machine training.
本発明の筋肉合成促進剤を摂取する対象には、例えば、スポーツ選手、スポーツ愛好者(アスリート)、生活習慣病の改善のために運動を必要とする者、高齢者などの健康増進のために運動を必要とする者、または筋肉損傷疾患(例えば、サルコペニア)を患い、運動により筋肉合成の促進を必要とする患者が挙げられる。また、この対象には、ヒト以外の動物(馬、牛などの家畜、犬、猫などの愛玩動物、動物園などで飼育されている鑑賞動物など)であってもよい。
Examples of subjects who take the muscle synthesis promoter of the present invention include, for example, athletes, sports enthusiasts (athletes), those who need exercise to improve lifestyle-related diseases, and elderly people for health promotion. Examples include those who require exercise, or patients who suffer from a muscle injury disease (eg, sarcopenia) and who need to promote muscle synthesis through exercise. Further, the target may be an animal other than a human (domestic animals such as horses and cows, pets such as dogs and cats, appreciation animals kept in zoos, etc.).
本発明の筋肉合成促進剤をタンパク質の即時吸収を必要とする対象に摂取させる(投与する)時期は、運動前であっても運動後であっても運動中であってもよい。ここで、この摂取させる時期は、好ましくは、運動後であり、より好ましくは、運動直後である。そして、運動により生じる骨格筋分解(異化)を抑制し、かつ、アミノ酸からタンパク質への同化を促進できる点で、この摂取させる時期は、好ましくは、運動直後のうち、運動終了後から3時間以内であり、より好ましくは、運動終了後から2時間以内であり、さらに好ましくは、運動終了後から1時間以内であり、特に好ましくは、運動終了後から30分以内である(Levenhagen et al. Am J physiol Endocrinol Metab (2001), 280, E982-E993参照)。
The time when the muscle synthesis promoter of the present invention is ingested (administered) to a subject in need of immediate protein absorption may be before exercise, after exercise, or during exercise. Here, the time of intake is preferably after exercise, more preferably immediately after exercise. In terms of suppressing skeletal muscle degradation (catabolism) caused by exercise and promoting assimilation from amino acids to proteins, the intake period is preferably within 3 hours after the end of exercise, immediately after exercise. More preferably, within 2 hours after the end of exercise, more preferably within 1 hour after the end of exercise, and particularly preferably within 30 minutes after the end of exercise (Levenhagenhaet al. Am J physiol Endocrinol Metab (2001), 280, E982-E993).
ホエイタンパク質と同等の即効的な筋肉合成促進作用とは、ホエイタンパク質を主成分とするタンパク質を経口摂取(投与)した場合にみられる、タンパク質の吸収の速度と同レベルの速度、およびその吸収に伴う筋肉合成促進作用と同レベルの作用を意味する。なお、筋肉合成促進作用には、アミノ酸からの筋肉タンパク質の同化作用も包含される。ここで、筋肉合成促進作用では、例えば、ラットの水泳試験後に、試験物質を投与してから1時間以内において、試験群の上肢三頭筋合成速度(FSR)を測定することによって確認することができる。すなわち、即効的な筋肉合成促進作用があるといわれているホエイタンパク質を主成分とするタンパク質を経口摂取した対照群のFSRに比べて、試験群のFSRが同程度や同程度以上の場合には、筋肉合成促進作用として有意であると判断できる(実施例1(2)参照)。また、筋肉合成促進作用には、筋肉タンパク質の分解抑制作用、すなわち、筋肉タンパク質からアミノ酸への異化防止作用も包含される。ここで、筋肉タンパク質の分解抑制作用では、例えば、ラットの水泳試験後に、試験物質を投与してから1時間以内において、3メチルヒスチジンの濃度を測定することによって確認することができる(実施例1(3)参照)。
Immediately effective muscle synthesis promoting effect equivalent to whey protein is the same level of protein absorption rate and absorption as observed when orally ingesting (administering) a protein mainly composed of whey protein. It means the same level of action as the accompanying muscle synthesis promoting action. The muscle synthesis promoting action includes an anabolic action of muscle protein from amino acids. Here, the muscle synthesis promoting action can be confirmed, for example, by measuring the triceps surae muscle synthesis rate (FSR) of the upper limb in the test group within 1 hour after administration of the test substance after the rat swimming test. it can. In other words, when the FSR of the test group is the same or higher than the FSR of the control group that orally ingested the protein mainly composed of whey protein, which is said to have an immediate effect of promoting muscle synthesis, Therefore, it can be judged that it is significant as a muscle synthesis promoting action (see Example 1 (2)). Further, the muscle synthesis promoting action includes a muscle protein degradation inhibiting action, that is, a catabolic preventing action from muscle protein to amino acid. Here, the degradation inhibitory action of muscle protein can be confirmed by measuring the concentration of 3 methylhistidine within 1 hour after administration of the test substance after, for example, a rat swimming test (Example 1). (See (3)).
「タンパク質量」とは、乳タンパク質、ホエイタンパク質またはカゼインタンパク質の各種のタンパク質に含まれるアミノ酸の高分子としてのタンパク質の量を意味する。「タンパク質量比」とは、乳タンパク質、ホエイタンパク質またはカゼインタンパク質の各種のタンパク質に含まれるアミノ酸の高分子としてのタンパク質の量の比率を意味する。ここで、タンパク質量は、例えば、食品成分表などの公知の情報に基づいて算出してもよく、また、ケルダール法やローリー法などの慣用の方法によって測定して算出してもよい。実際に、ケルダール法の場合には、各種のタンパク質に含まれる窒素を測定し、その値に、窒素-タンパク質換算係数(通常 6.25)を乗じて算出することができる。
"Protein amount" means the amount of protein as a polymer of amino acids contained in various proteins such as milk protein, whey protein or casein protein. “Protein amount ratio” means the ratio of the amount of protein as a polymer of amino acids contained in various proteins such as milk protein, whey protein, or casein protein. Here, the amount of protein may be calculated based on known information such as a food composition table, or may be calculated by measuring by a conventional method such as Kjeldahl method or Raleigh method. Actually, in the case of the Kjeldahl method, it can be calculated by measuring nitrogen contained in various proteins and multiplying the value by a nitrogen-protein conversion factor (usually 6.25).
本発明に用いられる乳タンパク質混合物は、ホエイタンパク質とカゼインタンパク質とを特定のタンパク質量比で含んでいればよく、特に限定されないが、別々に分離や精製されたホエイタンパク質とカゼインタンパク質とを特定のタンパク質量比になるように混合して調製してもよいし、あるいは、別々に分離や精製されていないホエイタンパク質とカゼインタンパク質とを既に特定のタンパク質量比で含んでいる原料(素材)や飲食品などを混合して調製してもよい。このとき、本発明に用いられる乳タンパク質混合物では、ホエイタンパク質やカゼインタンパク質の分離工程や精製工程を必要とせず、それらの製造費が安価である点で、ホエイタンパク質とカゼインタンパク質とを既に特定のタンパク質量比で含んでいる原料や飲食品などを主要な成分とし、必要に応じて、別々に精製されたホエイタンパク質やカゼインタンパク質とを特定のタンパク質量比になるように混合して調製することが好ましい。
The milk protein mixture used in the present invention is not particularly limited as long as it contains whey protein and casein protein in a specific protein amount ratio, but the whey protein and casein protein separated and purified separately are not specifically limited. It may be prepared by mixing so as to obtain a protein amount ratio, or a raw material (material) or food and drink that already contains whey protein and casein protein that have not been separated or purified separately in a specific protein amount ratio You may mix and prepare goods. At this time, the milk protein mixture used in the present invention does not require a separation step or purification step of whey protein or casein protein, and the production cost thereof is low, so that whey protein and casein protein are already specified. Prepared by mixing the raw materials and foods and drinks that are contained in the protein content ratio as the main components, and mixing the whey protein and casein protein purified separately as needed to achieve a specific protein content ratio. Is preferred.
カゼインタンパク質と別々に分離や精製されたホエイタンパク質には、例えば、ホエイの原液(甘性ホエイ、酸ホエイなど)、その濃縮物、その乾燥物(ホエイ粉など)、その凍結物、その加水分解物など、および、これらの還元溶液などを用いることができる。さらに、脱塩ホエイ、ホエイタンパク質濃縮物(WPC)、ホエイタンパク質精製物(WPI)、α-ラクトアルブミン(α-La)、β-ラクトグロブリン(β-Lg)、免疫グロブリン、ラクトフェリンなど、および、これらの還元溶液を用いることができる。そして、ホエイタンパク質と別々に分離や精製されたカゼインタンパク質には、例えば、カゼインの分離物(フレッシュチーズなどのナチュラルチーズ、ナトリウムカゼイネート、カルシウムカゼイネートなど)、その濃縮物、その乾燥物、その凍結物、その加水分解物など、および、これらの還元溶液などを用いることができる。さらに、α-カゼイン、β-カゼイン、κ-カゼインなどの精製物、および、これらの還元溶液を用いることができる。また、ホエイタンパク質とカゼインタンパク質とを既に特定のタンパク質量比で含んでいる原料や飲食品には、例えば、生乳、殺菌乳(牛乳など)、脱脂乳、成分調整牛乳、加工乳、乳製品(濃縮乳、粉乳、練乳、発酵乳(ヨーグルトなど)、乳酸菌飲料、プロセスチーズ類、アイスクリーム類、クリーム類)、乳タンパク質濃縮物(MPC)、その濃縮物、その乾燥物、その凍結物、その加水分解物など、および、これらの還元溶液などを用いることができる。このとき、これらには、市販品を入手して用いてもよいし、自ら調製して用いてもよい。
Examples of whey protein separated and purified separately from casein protein include whey stock solutions (sweet whey, acid whey, etc.), concentrates, dried products (whey powder, etc.), frozen products, hydrolyzed products, etc. And reducing solutions thereof. Further, desalted whey, whey protein concentrate (WPC), purified whey protein (WPI), α-lactalbumin (α-La), β-lactoglobulin (β-Lg), immunoglobulin, lactoferrin, and the like, and These reducing solutions can be used. Casein protein separated and purified separately from whey protein includes, for example, casein isolate (natural cheese such as fresh cheese, sodium caseinate, calcium caseinate), its concentrate, its dried product, its A frozen material, a hydrolyzate thereof, a reducing solution thereof, and the like can be used. Furthermore, purified products such as α-casein, β-casein, and κ-casein, and reducing solutions thereof can be used. In addition, raw materials and foods and beverages that already contain whey protein and casein protein in a specific protein ratio include, for example, raw milk, pasteurized milk (such as milk), skim milk, component-adjusted milk, processed milk, and dairy products ( Concentrated milk, powdered milk, condensed milk, fermented milk (yogurt, etc.), lactic acid bacteria beverages, processed cheeses, ice creams, creams), milk protein concentrate (MPC), its concentrate, its dried product, its frozen product, its Hydrolysates and the like, and reducing solutions thereof can be used. At this time, you may obtain and use a commercial item for these, and may prepare and use it for themselves.
本発明で用いられる乳タンパク質混合物は、特定のタンパク質量比のホエイタンパク質とカゼインタンパク質とから構成され、具体的には、ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20であり、好ましくは2~10であり、より好ましくは2~6であり、さらに好ましくは2~4であり、特に好ましくは2~3.5である。なお、本発明で用いられる乳タンパク質混合物では、カゼインタンパク質とホエイタンパク質とのタンパク質量比(カゼインタンパク質/ホエイタンパク質)が意図的に調整(設計)されている点で、従来技術とは大きく異なっている。
The milk protein mixture used in the present invention is composed of whey protein and casein protein having a specific protein amount ratio. Specifically, the protein amount ratio of casein protein to whey protein (casein protein / whey protein) is 2 to 20, preferably 2 to 10, more preferably 2 to 6, still more preferably 2 to 4, and particularly preferably 2 to 3.5. In the milk protein mixture used in the present invention, the protein ratio (casein protein / whey protein) between casein protein and whey protein is intentionally adjusted (designed), which is greatly different from the conventional technology. Yes.
本発明の筋肉合成促進剤は、耐熱性(熱安定性)が高く、耐熱効果を奏する。ここで、耐熱効果を奏するとは、特定の温度で処理しても、タンパク質が熱変性により固化(凝集)しないことを意味し、具体的には、牛乳の一般的な加工処理で用いられる条件や方法にて加熱殺菌しても、タンパク質が熱変性しないことを意味する。すなわち、耐熱効果を奏するとは、本発明の筋肉合成促進剤では、より具体的には、62~65℃、30分間で加熱殺菌(LTLT処理:低温長時間加熱)するか、あるいは、これと同程度以上の殺菌効果を有する方法として、例えば、120~150℃、1~30秒で加熱殺菌(UHT処理:超高温加熱)するか、72℃以上、15秒以上で加熱殺菌(HTST処理:高温短時間加熱)するか、75℃以上、15分以上で加熱殺菌するなどしても、タンパク質が熱変性しにくいことを意味する。このとき、加熱殺菌の方法には、タンクなどを用いて処理液を攪拌しながら加熱保持するバッチ式、プレート式熱交換器やチューブ式熱交換器を用いた間接加熱方式、スチームインジェクション式加熱装置やスチームインフュージョン式加熱装置を用いた直接加熱方式、ジュール加熱装置などを用いた通電加熱方式などの公知の方法を用いることができる。
The muscle synthesis promoter of the present invention has high heat resistance (thermal stability) and exhibits a heat resistance effect. Here, having a heat-resistant effect means that the protein does not solidify (aggregate) due to heat denaturation even when it is treated at a specific temperature. Specifically, it is a condition used in general processing of milk. This means that the protein is not heat denatured even if heat-sterilized by the method. More specifically, the muscle synthesis promoter of the present invention has a heat resistance effect. More specifically, it is heat sterilized (LTLT treatment: low temperature and long time heating) at 62 to 65 ° C. for 30 minutes, or As a method having a sterilizing effect of the same degree or more, for example, heat sterilization (UHT treatment: ultra-high temperature heating) at 120 to 150 ° C. for 1 to 30 seconds, or heat sterilization (HTST treatment: 72 ° C. for 15 seconds or more): This means that the protein is not easily heat denatured even if it is heated at high temperature for a short time or sterilized by heating at 75 ° C. or higher for 15 minutes or longer. At this time, the heat sterilization method includes a batch type in which the processing liquid is heated and held using a tank or the like, an indirect heating type using a plate type heat exchanger or a tube type heat exchanger, and a steam injection type heating device. And a known method such as a direct heating method using a steam infusion type heating device or a current heating method using a Joule heating device can be used.
本発明の一つの実施態様によれば、例えば、本発明の筋肉合成促進剤では、前記乳タンパク質混合物が総タンパク質量で一食あたり0.13g以上/kg体重となるように摂取(投与)され、具体的には、0.13~0.7g/kg体重であり、好ましくは0.13~0.6g/kg体重、より好ましくは0.13~0.5g/kg体重、さらに好ましくは0.15~0.4g/kg体重、特に好ましくは0.2~0.4g/kg体重となるように摂取(投与)される。ここで、対象の代表的な体重は、約60kgと見積もっている。
According to one embodiment of the present invention, for example, in the muscle synthesis promoter of the present invention, the milk protein mixture is ingested (administered) so that the total protein amount is 0.13 g / kg body weight or more per meal, Specifically, the weight is 0.13 to 0.7 g / kg body weight, preferably 0.13 to 0.6 g / kg body weight, more preferably 0.13 to 0.5 g / kg body weight, still more preferably 0.00. It is ingested (administered) so as to be 15 to 0.4 g / kg body weight, particularly preferably 0.2 to 0.4 g / kg body weight. Here, the typical weight of the subject is estimated to be about 60 kg.
「一食」とは、タンパク質の即時吸収を必要とする状態の一回ごとを意味し、例えば、本発明の筋肉合成促進剤では、一食で一息に(一度に)摂取せず、数度に分けて摂取してもよい。本発明の筋肉合成促進剤をタンパク質の即時吸収を必要とする対象に摂取させる(投与する)時期は、数度に分けて摂取する場合には、血流中のアミノ酸濃度を即効的に高められる点で、好ましくは、運動終了後から2時間以内であり、より好ましくは、運動終了後から1時間以内であり、さらに好ましくは、運動終了後から30分以内であり、特に好ましくは、運動終了後から5分以内である。
The term “one meal” means one time in a state requiring immediate absorption of protein. For example, in the muscle synthesis promoter of the present invention, a single meal is not taken at a time (at a time), but several times. May be taken separately. When the muscle synthesis promoter of the present invention is ingested (administered) to a subject in need of immediate protein absorption, the amino acid concentration in the bloodstream can be increased immediately when it is ingested in several degrees. In this respect, it is preferably within 2 hours after the end of exercise, more preferably within 1 hour after the end of exercise, more preferably within 30 minutes after the end of exercise, and particularly preferably the end of exercise. Within 5 minutes later.
本発明の筋肉合成促進剤をタンパク質の即時吸収を必要とする対象に摂取させる(投与する)方法は、経口摂取(経口投与)、経腸投与、胃ろうなどから、その対象および用途により、適宜選択することができるが、好ましくは経口摂取である。
The method for ingesting (administering) the muscle synthesis promoter of the present invention to a subject in need of immediate protein absorption can be appropriately selected from oral ingestion (oral administration), enteral administration, gastric fistula and the like depending on the subject and application. Although it can be selected, it is preferably taken orally.
本発明の筋肉合成促進剤は、その効果が奏される限り、如何なる形態もとることができるが、例えば、固体状、液状、ゲル状、糊状、ペースト状などの形態が挙げられる。本発明の筋肉合成促進剤では、固体状のうち、粉末状であってもよいし、顆粒状であってもよいし、カプセル状であってもよいし、ブロック状であってもよいが、加工適性が良好な点で、好ましくは、液状である。ここで、例えば、本発明の筋肉合成促進剤では、水分を含んでいても、耐熱性を有しているため、十分に加熱殺菌することができる。したがって、例えば、本発明の筋肉合成促進剤では、冷蔵状態および常温で長期間の保存期限を設定することができる。本発明の筋肉合成促進剤では、水分の含有量は、適宜調整することができ、具体的には、10~95質量%であってもよく、好ましくは20~95質量%であり、より好ましくは30~90質量%であり、さらに好ましくは40~90質量%である。本発明の筋肉合成促進剤では、水分の含有量(あるいは固形分の含有量)を所定値に調整することで、水分の含有量が高い従来の健康ドリンクやスポーツ飲料などとは異なり、筋肉合成を効果的に促進することができる。
The muscle synthesis promoter of the present invention can take any form as long as the effect is exerted, and examples thereof include a solid form, a liquid form, a gel form, a paste form, and a paste form. In the muscle synthesis promoter of the present invention, among solids, it may be powder, granule, capsule, block, In view of good processability, it is preferably a liquid. Here, for example, in the muscle synthesis promoter of the present invention, even if it contains moisture, it has heat resistance and can be sufficiently sterilized by heating. Therefore, for example, in the muscle synthesis promoter of the present invention, a long-term storage period can be set in a refrigerated state and at room temperature. In the muscle synthesis promoter of the present invention, the water content can be appropriately adjusted. Specifically, it may be 10 to 95% by mass, preferably 20 to 95% by mass, and more preferably. Is 30 to 90% by mass, more preferably 40 to 90% by mass. In the muscle synthesis promoter of the present invention, by adjusting the water content (or solid content) to a predetermined value, unlike conventional health drinks and sports drinks with high water content, muscle synthesis Can be effectively promoted.
本発明の別の実施態様によれば、例えば、本発明の筋肉合成促進剤は、一食あたりの単位包装形態からなり、該単位包装形態中に、前記乳タンパク質混合物を、一食摂取量として総タンパク質量で8g以上に調整してなるものが望ましく、具体的には、8~40g、好ましくは8~20g、より好ましくは9~20g、さらに好ましくは9~15g、特に好ましくは10~15gとなるように調整してなるものである。ここで、「一食あたりの単位包装形態」からなるとは、一食あたりの摂取量があらかじめ定められた形態のものであり、例えば、特定量を経口摂取し得る飲食品として、一般食品のみならず、飲料(ドリンク剤など)、健康補助食品、保健機能食品、サプリメントなどの形態を意味する。「一食あたりの単位包装形態」では、例えば、液状の飲料、ゲル状・糊状・ペースト状のゼリー、粉末状・顆粒状・カプセル状・ブロック状の固体状の食品などの場合には、金属缶、ガラスビン(ボトルなど)、プラスチック容器(ペットボトルなど)、パック、パウチ、フィルム容器、紙箱などの包装容器で特定量(用量)を規定できる形態、あるいは、一食あたりの摂取量(用法、用量)を包装容器やホームページなどに表示することで特定量を規定できる形態が挙げられる。
According to another embodiment of the present invention, for example, the muscle synthesis promoter of the present invention comprises a unit package form per serving, and the milk protein mixture is added to the total amount of food intake in the unit package form. It is desirable that the amount of protein is adjusted to 8 g or more, specifically, 8 to 40 g, preferably 8 to 20 g, more preferably 9 to 20 g, still more preferably 9 to 15 g, particularly preferably 10 to 15 g. It adjusts so that it may become. Here, `` consisting of a unit packaging form per meal '' is a form in which the intake amount per meal is determined in advance, for example, as a food and drink that can be taken orally in a specific amount, not only general foods, It means forms such as beverages (drinks, etc.), health supplements, health functional foods, and supplements. In "unit packaging form per meal", for example, in the case of liquid beverages, gel-like, paste-like, paste-like jelly, powder-like, granule-like, capsule-like, block-like solid foods, etc. A specific amount (dose) can be defined in packaging containers such as cans, glass bottles (such as bottles), plastic containers (such as plastic bottles), packs, pouches, film containers, paper boxes, etc., or intake per serving (usage, dose) ) Is displayed on a packaging container, a homepage, etc., and the form which can prescribe | regulate specific quantity is mentioned.
本発明の別の実施態様によれば、例えば、本発明の筋肉合成促進剤では、その形態がいわゆる健康ドリンクである場合には、8~40gの前記乳タンパク質が懸濁あるいは溶解された飲料が一食あたりの飲み切りの容量(用量)で、100~1000mlとなるように水分量で調整して、金属缶、ガラスビン(ボトルなど)、プラスチック容器(ペットボトルなど)などの包装容器に入れられている(充填されている)形態が挙げられる。あるいは、8~40gの前記乳タンパク質が懸濁あるいは溶解された飲料が一食あたりの摂取量(用法、用量)(例えば、100~1000ml)を包装容器やホームページなどに表示して、数食分(数回分)を一括した容量で、大容量の包装容器などに入れられている(充填されている)形態が挙げられる。
According to another embodiment of the present invention, for example, when the form of the muscle synthesis promoter of the present invention is a so-called health drink, 8 to 40 g of the beverage in which the milk protein is suspended or dissolved is provided. The capacity (dose) of a single drink per meal is adjusted by the amount of water so that it is 100 to 1000 ml, and is placed in a packaging container such as a metal can, a glass bottle (such as a bottle), or a plastic container (such as a plastic bottle). (Filled) form. Alternatively, 8 to 40 g of the above-described milk protein suspension or dissolved beverage is displayed on a packaging container or homepage as the amount of intake (usage, dose) (for example, 100 to 1000 ml) per serving, and several servings (several (Batch) is a collective capacity, and is a form that is put (filled) in a large-capacity packaging container or the like.
本発明の筋肉合成促進剤は、所定の乳タンパク質混合物を含むように製造される限り、その製造工程(製造手順)は制限されないが、例えば、牛乳、成分調整牛乳、加工乳、乳飲料などの製造工程に基づいて製造することができる。本発明の筋肉合成促進剤は、例えば、公知の製造方法(製造手法)に従って、生乳(原乳)、殺菌乳、濃縮乳、粉乳、還元乳に対して、乳タンパク質や乳脂肪などの各種成分を配合(調整)することで製造することができるし、あるいは、成分調整牛乳や加工乳(低脂肪乳や無脂肪乳など)に対して、乳タンパク質や乳脂肪などの各種成分を配合(調整)することで製造することもできる。
As long as the muscle synthesis promoter of the present invention is manufactured so as to contain a predetermined milk protein mixture, its manufacturing process (manufacturing procedure) is not limited. For example, milk, ingredient-adjusted milk, processed milk, milk drink, etc. It can manufacture based on a manufacturing process. The muscle synthesis promoter of the present invention includes various components such as milk protein and milk fat with respect to raw milk (raw milk), sterilized milk, concentrated milk, powdered milk, and reduced milk according to a known manufacturing method (manufacturing method). It can be manufactured by blending (adjusting) the ingredients, or various ingredients such as milk protein and milk fat can be blended (adjusted) with component-adjusted milk and processed milk (such as low-fat milk and non-fat milk). ) Can also be manufactured.
本発明の一つの実施態様によれば、例えば、本発明の筋肉合成促進剤では、筋肉合成促進剤を含んでなる組成物を提供することができる。すなわち、本発明の筋肉合成促進剤は、そのまま単独で使用することができるが、筋肉合成促進機能が発揮される限りにおいて、飲食品や医薬品などの種々の経口摂取用(経口投与用)の組成物に対して、原料(素材)や添加剤などとして含ませることもでき、即効的な筋肉合成促進効果を有する組成物(例えば、医薬組成物や飲食品組成物)を得ることができる。よって、本発明の一つの実施態様によれば、本発明の筋肉合成促進剤を含んでなる組成物が提供される。
According to one embodiment of the present invention, for example, the muscle synthesis promoter of the present invention can provide a composition comprising a muscle synthesis promoter. That is, the muscle synthesis promoter of the present invention can be used alone as it is, but as long as the muscle synthesis promotion function is exhibited, various compositions for oral intake (for oral administration) such as foods and drinks and pharmaceuticals. A composition (for example, a pharmaceutical composition or a food / beverage product composition) having an immediate effect of promoting muscle synthesis can also be obtained. Therefore, according to one embodiment of the present invention, a composition comprising the muscle synthesis promoter of the present invention is provided.
「飲食品」(飲食品組成物)とは、医薬品(医薬組成物)以外のものであって、溶液、懸濁液、乳濁液、粉末、固体成形物など、経口摂取できる形態であればよく、特に限定されない。飲食品とは、具体的には、即席麺、レトルト食品、缶詰、電子レンジ食品、即席スープ・みそ汁類、フリーズドライ食品などの即席食品類;清涼飲料、果汁飲料、野菜飲料、豆乳飲料、コーヒー飲料、茶飲料、粉末飲料、濃縮飲料、アルコール飲料などの飲料類;パン、パスタ、麺、ケーキミックス、パン粉などの小麦粉製品;飴、キャラメル、チューイングガム、チョコレート、クッキー、ビスケット、ケーキ、パイ、スナック、クラッカー、和菓子、デザート菓子などの菓子類;ソース、トマト加工調味料、風味調味料、調理ミックス、たれ類、ドレッシング類、つゆ類、カレー・シチューの素類などの調味料;加工油脂、バター、マーガリン、マヨネーズなどの油脂類;乳飲料、発酵乳(ヨーグルトなど)、乳酸菌飲料、ナチュラルチーズ、プロセスチーズ類、アイスクリーム類、クリーム類などの乳製品;農産缶詰、ジャム・マーマレード類、シリアルなどの農産加工品;冷凍食品などが挙げられる。
"Food and drink" (food and drink composition) is something other than a pharmaceutical product (pharmaceutical composition), as long as it can be taken orally, such as a solution, suspension, emulsion, powder, solid molded product, etc. Well, not particularly limited. Specific examples of food and drink include instant noodles, retort food, canned food, microwave food, instant soup and miso soup, freeze-dried food, etc .; soft drinks, fruit juice drinks, vegetable drinks, soy milk drinks, coffee Beverages such as beverages, tea beverages, powdered beverages, concentrated beverages, alcoholic beverages; flour products such as bread, pasta, noodles, cake mixes, bread crumbs; strawberries, caramel, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks , Crackers, Japanese confectionery, dessert confectionery, etc .; sauces, tomato processing seasonings, flavor seasonings, cooking mixes, sauces, dressings, soups, curry and stew ingredients; processed oils and fats, butter Oils and fats such as margarine and mayonnaise; milk drinks, fermented milk (yogurt, etc.), lactic acid bacteria drinks, natural tea 'S, process cheese, ice cream, dairy products such as cream; agricultural canning, jam, marmalade such, processed agricultural products such as serial; such as frozen food, and the like.
また、飲食品には、健康食品、機能性食品、栄養補助食品、特定保健用食品、病者用の食品、乳幼児用の調整粉乳、妊産婦用もしくは授乳婦用の粉乳、または即効的な筋肉合成促進のために用いられる物である旨の表示を付した飲食品のような分類のものも包含される。
Foods and drinks include health foods, functional foods, dietary supplements, foods for specified health use, foods for the sick, infant formula, powdered milk for pregnant or lactating women, or rapid muscle synthesis. The thing of classification like the food-drinks which attached | subjected the indication that it is a thing used for promotion is also included.
「医薬品」(医薬組成物)とは、製剤化のために許容されうる添加剤を併用して、常法に従って、経口製剤または非経口製剤として調製されたものである。医薬品が経口製剤の場合には、錠剤、散剤、細粒剤、顆粒剤、カプセル剤、丸剤、徐放剤などの固形製剤、溶液、懸濁液、乳濁液などの液状製剤の形態をとることができる。また、医薬品が非経口製剤の場合には、注射剤や座剤の形態をとることができる。なお、患者への摂取(投与)の簡易性などの点から、医薬品では、経口製剤であることが好ましい。ここで、製剤化のために許容されうる添加剤には、例えば、賦形剤、安定剤、防腐剤、湿潤剤、乳化剤、滑沢剤、甘味料、着色料、香料、緩衝剤、酸化防止剤、pH調整剤などが挙げられる。
“Pharmaceuticals” (pharmaceutical compositions) are those prepared as oral preparations or parenteral preparations in accordance with conventional methods, using additives that are acceptable for formulation. When the pharmaceutical is an oral preparation, it should be in the form of a solid preparation such as a tablet, powder, fine granule, granule, capsule, pill or sustained release, or a liquid preparation such as a solution, suspension or emulsion. Can take. Moreover, when a pharmaceutical is a parenteral formulation, it can take the form of an injection or a suppository. In terms of ease of ingestion (administration) to a patient, the pharmaceutical is preferably an oral preparation. Here, additives that are acceptable for formulation include, for example, excipients, stabilizers, preservatives, wetting agents, emulsifiers, lubricants, sweeteners, coloring agents, fragrances, buffers, antioxidants. Agents, pH adjusters and the like.
本発明の筋肉合成促進剤は、耐熱効果を奏する。したがって、本発明の筋肉合成促進剤を配合(添加、混合)した組成物では、本発明の筋肉合成促進剤が耐熱効果を奏することから、好ましくは、液状の製品形態として提供することができると共に、ホットベンダーなどを用いた加温販売用の製品形態として提供することができる。
The muscle synthesis promoter of the present invention has a heat resistance effect. Therefore, in the composition in which the muscle synthesis promoter of the present invention is blended (added, mixed), the muscle synthesis promoter of the present invention has a heat-resistant effect, so that it can be preferably provided as a liquid product form. It can be provided as a product form for warm sales using a hot vendor or the like.
また、本発明の筋肉合成促進剤を配合(添加、混合)した組成物の形態は、その効果が奏される限り、如何なる形態もとることができるが、例えば、固体状、液状、ゲル状、糊状、ペースト状などの形態が挙げられる。本発明の筋肉合成促進剤を配合した組成物では、固体状のうち、粉末状であってもよいし、顆粒状であってもよいし、カプセル状であってもよいし、ブロック状であってもよいが、加工適性が良好な点で、好ましくは、液状である。
The composition of the muscle synthesis promoter of the present invention may be in any form as long as the effect is exerted, for example, solid, liquid, gel, Examples include pasty and pasty forms. The composition containing the muscle synthesis promoter of the present invention may be in the form of a solid, powder, granule, capsule, or block. However, it is preferably a liquid in terms of good processability.
本発明の一つの実施態様によれば、本発明の筋肉合成促進剤を配合(添加、混合)および加熱殺菌してなる飲食品であって、一食あたりの単位包装形態からなり、該単位包装形態中に、前記乳タンパク質混合物を、一食摂取量として総タンパク質量で8~40gに調整したものが望ましく、好ましくは8~20g、より好ましくは9~20g、さらに好ましくは9~15g、特に好ましくは10~15gとなるように調整してなる、タンパク質の即時吸収による筋肉合成促進作用が付与された、飲食品およびその製造方法が提供される。ここで、所定の成分に「配合(添加、混合)および加熱殺菌」する操作(工程)とは、最終的に所定の成分に調整され、かつ殺菌される操作であればよく、特に限定されないが、必要な全部の成分を混合して所定の成分に調整してから一括して加熱殺菌する操作や、必要な個別の成分を別々に加熱殺菌してから混合して所定の成分に調整する操作などが挙げられる。したがって本発明では、この配合(添加、混合)と加熱殺菌の順番や回数は任意である。
According to one embodiment of the present invention, it is a food / beverage product obtained by blending (adding, mixing) and heat-sterilizing the muscle synthesis promoter of the present invention, comprising a unit packaging form per serving, and the unit packaging form Among them, it is desirable that the milk protein mixture is adjusted to a total protein amount of 8 to 40 g as a single meal intake, preferably 8 to 20 g, more preferably 9 to 20 g, still more preferably 9 to 15 g, particularly preferably. Food / beverage products and methods for producing the same are provided, which are provided with an effect of promoting muscle synthesis by immediate absorption of protein, adjusted to 10 to 15 g. Here, the operation (process) of “mixing (addition, mixing) and heat sterilization” to a predetermined component is not particularly limited as long as the operation is finally adjusted to a predetermined component and sterilized. Operation that mixes all necessary components and adjusts them to the prescribed components and then heat sterilizes them together, or operation that sterilizes the necessary individual components separately and mixes them to adjust them to the prescribed components Etc. Therefore, in the present invention, the order and number of times of this blending (addition, mixing) and heat sterilization are arbitrary.
このとき、前記飲食品(本発明の飲食品)は、好ましくは、包装容器詰の飲食品であり、より好ましくは、加熱販売用の包装容器詰の飲食品である。すなわち、前記飲食品には、耐熱性があるため、これを加温販売しても、タンパク質が極端に変性することはない。したがって、従来のホエイタンパク質のみまたはホエイタンパク質を主成分として構成された飲食品では、暖かい飲食品として、冬場の戸外などで提供できなかったのに対して、前記飲食品では、暖かい飲食品として、冬場(特に寒冷の状況)の戸外などで提供することができ、消費者などに摂取(飲用)させることができる。そのため、新たなニーズに対応した筋肉合成促進効果のある飲食品の実用化が期待できる。ここで、加温販売用の飲食品には、例えば、ホットベンダーに収納された、あるいは湯煎された、加温販売用の飲料や加温販売用の食品、ならびに、必要量を調理器具に入れて、ガスコンロ、電熱コンロ、マイクロウエーブなどで加熱された、加温販売用の飲料や加温販売用の食品が挙げられる。なお、加温販売では、一般的には30~80℃前後または50~80℃前後などで保管される。
At this time, the food / beverage product (the food / beverage product of the present invention) is preferably a food / beverage product packed in a packaging container, and more preferably a food / beverage product packed in a packaging container for heat sale. That is, since the food and drink have heat resistance, the protein will not be extremely denatured even if it is heated and sold. Therefore, in the food and drink composed only of the conventional whey protein or the whey protein as a main component, as a warm food and drink, it could not be provided outdoors in winter, etc., whereas in the food and drink, as a warm food and drink, It can be provided outdoors in winter (especially in cold conditions) and can be consumed (drinked) by consumers. Therefore, the practical use of the food-drinks with the effect of accelerating muscle synthesis corresponding to new needs can be expected. Here, in the food and drink for hot sale, for example, a hot sale beverage or a hot sale food stored in a hot vendor or hot water, and a necessary amount are put in a cooking utensil. In addition, heated beverages and heated foods heated by gas stoves, electric heating stoves, microwaves, and the like can be mentioned. In warm sales, it is generally stored at around 30-80 ° C or around 50-80 ° C.
本発明の好ましい実施態様によれば、前記飲食品は、乳飲料である。前記飲食品には、耐熱性があるため、これを加熱殺菌などしても、タンパク質が極端に変性することがないためである。ここで、「乳飲料」とは、乳固形分(無脂乳固形分と乳脂肪分を合わせたもの)を3.0重量%以上で含む飲料を意味する。この乳飲料には、例えば、ビタミン、ミネラル、オリゴ糖、乳糖、果汁などを配合しうる。
According to a preferred embodiment of the present invention, the food or drink is a milk drink. This is because the food and drink have heat resistance, and thus the protein is not extremely denatured even if it is heat sterilized. Here, “milk beverage” means a beverage containing milk solids (a combination of nonfat milk solids and milk fat) at 3.0% by weight or more. For example, vitamins, minerals, oligosaccharides, lactose, fruit juice and the like can be blended in the milk beverage.
本発明の飲食品の製造方法では、所定の乳タンパク質混合物を(所定の濃度で)含むように飲食品が製造される限り、その製造工程(製造手順)は制限されないが、例えば、牛乳、成分調整牛乳、加工乳、乳飲料などの製造工程に基づいて製造することができる。本発明の飲食品は、例えば、公知の製造方法(製造手法)に従って、生乳(原乳)、殺菌乳、濃縮乳、粉乳、還元乳に対して、乳タンパク質や乳脂肪などの各種成分を配合(調整)することで製造することができるし、成分調整牛乳や加工乳(低脂肪乳や無脂肪乳など)に対して、乳タンパク質や乳脂肪などの各種成分を配合(調整)することで製造することもできる。
In the method for producing a food or drink according to the present invention, the production process (manufacturing procedure) is not limited as long as the food or drink is produced so as to contain a predetermined milk protein mixture (at a predetermined concentration). It can manufacture based on manufacturing processes, such as adjusted milk, processed milk, and a milk drink. The food / beverage products of this invention mix | blend various components, such as milk protein and milk fat, with respect to raw milk (raw milk), pasteurized milk, concentrated milk, powdered milk, reduced milk, for example according to a well-known manufacturing method (manufacturing method). It can be manufactured by (adjusting), and by blending (adjusting) various ingredients such as milk protein and milk fat into ingredient-adjusted milk and processed milk (such as low-fat milk and non-fat milk) It can also be manufactured.
本発明の別の実施態様によれば、ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、生乳、殺菌乳、濃縮乳、粉乳および還元乳からなる群から選択される一種以上と混合および加熱殺菌してなる乳飲料であって、乳タンパク質混合物の総タンパク質量で8g以上/200ml、好ましくは8~20g/200ml、より好ましくは9~20g/200ml、さらに好ましくは9~15g/200ml、特に好ましくは10~15g/200mlに調整され、かつ、乳脂肪量で8g以下/200ml、好ましくは0.1~8g/200ml、より好ましくは0.1~6g/200ml、さらに好ましくは0.5~4g/200ml、特に好ましくは0.5~3g/200mlに調整してなる、タンパク質の即時吸収による筋肉合成促進作用が付与された、包装容器詰の乳飲料が提供される。
According to another embodiment of the present invention, a milk protein mixture containing casein protein and whey protein, wherein the protein amount ratio of casein protein to whey protein (casein protein / whey protein) is 2 to 20, A milk beverage mixed and heat-sterilized with one or more selected from the group consisting of milk, concentrated milk, powdered milk and reduced milk, wherein the total protein content of the milk protein mixture is 8 g / 200 ml, preferably 8-20 g / 200 ml, more preferably 9 to 20 g / 200 ml, even more preferably 9 to 15 g / 200 ml, particularly preferably 10 to 15 g / 200 ml, and the milk fat amount is 8 g or less / 200 ml, preferably 0.1 to 8 g / 200 ml, more preferably 0.1-6 g / 200 ml, Provided is a packaged container-packed milk beverage that is preferably adjusted to 0.5 to 4 g / 200 ml, particularly preferably 0.5 to 3 g / 200 ml, and has an effect of promoting muscle synthesis by immediate protein absorption. .
本発明のさらに別の実施態様によれば、ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含むからなる乳タンパク質混合物を、生乳、殺菌乳、濃縮乳、粉乳および還元乳からなる群から選択される一種以上に添加する工程、および加熱殺菌する工程を含んでなる包装容器詰の乳飲料の製造方法であって、乳タンパク質混合物の総タンパク質量で8g以上/200ml、好ましくは8~20g/200ml、より好ましくは9~20g/200ml、さらに好ましくは9~15g/200ml、特に好ましくは10~15g/200mlに調整され、かつ、乳脂肪量で8g以下/200ml、好ましくは0.1~8g/200ml、より好ましくは0.1~6g/200ml、さらに好ましくは0.5~4g/200ml、特に好ましくは0.5~3g/200mlに調整してなる、タンパク質の即時吸収による筋肉合成促進作用が付与された、包装容器詰の乳飲料の製造方法が提供される。
According to yet another embodiment of the present invention, a milk protein mixture comprising casein protein and whey protein, wherein the protein amount ratio of casein protein to whey protein (casein protein / whey protein) is 2 to 20, A method for producing a packaged-packed milk beverage comprising a step of adding to one or more selected from the group consisting of raw milk, pasteurized milk, concentrated milk, powdered milk and reduced milk, and a heat sterilization step, wherein the milk protein The total protein amount of the mixture is adjusted to 8 g / 200 ml, preferably 8 to 20 g / 200 ml, more preferably 9 to 20 g / 200 ml, still more preferably 9 to 15 g / 200 ml, particularly preferably 10 to 15 g / 200 ml, and Milk fat content is 8g or less / 200ml, preferably 0.1-8g 200 ml, more preferably 0.1 to 6 g / 200 ml, further preferably 0.5 to 4 g / 200 ml, particularly preferably 0.5 to 3 g / 200 ml. Provided is a method for producing a packaged dairy beverage.
「還元乳」とは、粉乳や濃縮乳などの乳原料を水に分散・溶解して調製した、液状乳を意味する。前記乳原料には、例えば、全脂粉乳、脱脂粉乳、全脂濃縮乳、脱脂濃縮乳、バター、クリーム、煉乳などが挙げられ、生乳、殺菌乳(牛乳など)、脱脂乳、成分調製牛乳、加工乳などから水分が除去されたものであれば、特に制限されず、これらは一種以上を混合して用いてもよい。前記乳飲料では、ホエイタンパク質の熱変性による凝集は見られず(実施例2参照)、したがって、本発明の筋肉合成促進剤と同様に、タンパク質の即時吸収効果を維持している。
“Reduced milk” means liquid milk prepared by dispersing and dissolving milk raw materials such as powdered milk and concentrated milk in water. Examples of the milk raw material include whole milk powder, skim milk powder, whole fat concentrated milk, nonfat concentrated milk, butter, cream, and unfinished milk. Raw milk, pasteurized milk (such as milk), skimmed milk, component-prepared milk, If water is removed from processed milk etc., it will not restrict | limit, These may mix and use 1 or more types. In the milk beverage, aggregation due to heat denaturation of the whey protein is not observed (see Example 2), and therefore, the immediate protein absorption effect is maintained as in the muscle synthesis promoter of the present invention.
本発明の別の実施態様によれば、ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、タンパク質の即時吸収を必要とする対象に摂取させることを含んでなる、筋肉合成促進方法が提供される。
According to another embodiment of the present invention, a milk protein mixture comprising casein protein and whey protein, wherein the protein content ratio of casein protein to whey protein (casein protein / whey protein) is 2 to 20, There is provided a method of promoting muscle synthesis comprising ingesting a subject in need of absorption.
本発明の好ましい実施態様によれば、ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、タンパク質の即時吸収を必要とする対象に摂取させることを含んでなる、筋肉合成促進方法(ヒトに対する医療行為を除く)が提供される。ここで、「ヒトに対する医療行為」とは、医師等の処方を必要として、ヒトに対して医薬品を摂取させる(投与する)行為などを意味する。本発明の筋肉合成促進方法は、本発明の筋肉合成促進剤について、本願明細書に記載された内容に従って実施することができる。
According to a preferred embodiment of the present invention, a milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is instantly absorbed by the protein. A method for promoting muscle synthesis (excluding medical practice for humans) comprising ingesting a subject in need thereof. Here, the “medical action for humans” means an action that requires a doctor or the like to ingest (administer) a medicine to a human. The muscle synthesis promoting method of the present invention can be carried out according to the contents described in the present specification for the muscle synthesis promoting agent of the present invention.
本発明の一つの好ましい実施態様によれば、本発明の筋肉合成促進方法において、前記乳タンパク質混合物を総タンパク質量で一食あたり0.13g以上/kg体重となるように摂取(投与)させることができ、具体的には、0.13~0.7g/kg体重であり、好ましくは0.13~0.6g/kg体重、より好ましくは0.13~0.5g/kg体重、さらに好ましくは0.15~0.4g/kg体重、特に好ましくは0.2~0.4g/kg体重となるように摂取させることができる。
According to one preferred embodiment of the present invention, in the muscle synthesis promoting method of the present invention, the milk protein mixture is ingested (administered) so that the total protein amount is 0.13 g / kg body weight or more per meal. Specifically, the weight is 0.13-0.7 g / kg body weight, preferably 0.13-0.6 g / kg body weight, more preferably 0.13-0.5 g / kg body weight, still more preferably It can be ingested so as to be 0.15 to 0.4 g / kg body weight, particularly preferably 0.2 to 0.4 g / kg body weight.
本発明の一つの好ましい実施態様によれば、本発明の筋肉合成促進方法において、前記乳タンパク質混合物を総タンパク質量で一食あたり8g以上となるように摂取させることができ、具体的には、8~40g、好ましくは8~20g、より好ましくは9~20g、さらに好ましくは9~15g、特に好ましくは10~15gとなるように摂取させることができる。
According to one preferred embodiment of the present invention, in the method for promoting muscle synthesis of the present invention, the milk protein mixture can be ingested so that the total protein amount is 8 g or more per serving. It can be ingested so as to be ˜40 g, preferably 8 to 20 g, more preferably 9 to 20 g, still more preferably 9 to 15 g, particularly preferably 10 to 15 g.
本発明の一つの実施態様によれば、本発明の筋肉合成促進方法において、前記乳タンパク質混合物を、タンパク質の即時吸収を必要する対象に加温した液状形態で摂取させることができる。
According to one embodiment of the present invention, in the muscle synthesis promotion method of the present invention, the milk protein mixture can be ingested in a heated liquid form to a subject that needs immediate absorption of the protein.
本発明の一つの実施態様によれば、タンパク質の即時吸収を必要とする対象の筋肉合成促進のための、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含んでなる、筋肉合成促進剤であって、ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である筋肉合成促進剤の使用が提供される。本発明の筋肉合成促進剤の使用は、本発明の筋肉合成促進剤について本明細書に記載された内容に従って実施することができる。
According to one embodiment of the present invention, there is provided a muscle synthesis promoting agent comprising a milk protein mixture comprising casein protein and whey protein for promoting muscle synthesis of a subject in need of immediate protein absorption. Thus, the use of a muscle synthesis promoter having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is provided. The use of the muscle synthesis promoter of the present invention can be carried out according to the contents described herein for the muscle synthesis promoter of the present invention.
本発明の一つの実施態様によれば、タンパク質の即時吸収を必要とする対象の筋肉合成を促進するための飲食品または医薬品の製造のための、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含んでなる、筋肉合成促進剤であって、ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である筋肉合成促進剤の使用が提供される。本発明の筋肉合成促進剤の使用は、本発明の筋肉合成促進剤について本明細書に記載された内容に従って実施することができる。
According to one embodiment of the present invention, there is provided a milk protein mixture comprising casein protein and whey protein for the manufacture of a food or beverage or pharmaceutical product for promoting muscle synthesis in a subject in need of immediate protein absorption. The use of a muscle synthesis promoter comprising a muscle synthesis promoter having a protein content ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is provided. The use of the muscle synthesis promoter of the present invention can be carried out according to the contents described herein for the muscle synthesis promoter of the present invention.
ところで、ここでは具体的な実験結果などは省略するが、本発明の一つの実施態様によれば、単に優れた筋肉合成促進作用(筋肉合成促進効果)を発揮するだけでなく、併せて優れた体水分保持作用(体水分保持効果)も発揮することができる。そのため、本発明では、従来のホエイタンパク質を主成分とする医薬品や飲食品などでは得られなかった特有の効果を期待できることとなる。
By the way, although specific experimental results and the like are omitted here, according to one embodiment of the present invention, not only an excellent muscle synthesis promoting action (muscle synthesis promoting effect) is exhibited but also an excellent performance is achieved. The body water retention action (body water retention effect) can also be exhibited. Therefore, in the present invention, it is possible to expect a specific effect that cannot be obtained with conventional pharmaceuticals and foods and drinks mainly composed of whey protein.
本発明を以下の実施例によって詳細に説明するが、本発明は、これらに限定されるものではない。
The present invention will be described in detail by the following examples, but the present invention is not limited thereto.
実施例1:乳タンパク質混合物による筋肉合成促進作用
(1)ラットの水泳試験
実験動物には、初期体重が140~160gのSD系雄ラット(日本クレア株式会社より入手した)を用いた。ラットでは、試験区(群)ごとで体重差が生じないように、9~10尾ずつで6つに分けた。全てのラットは、明期7時~19時、暗期19時~7時として、室温の22±2℃の条件下にて、ステンレス製ケージ内で個体別に飼育された。 Example 1: Muscle synthesis promoting action by milk protein mixture (1) Rat swimming test SD male rats (obtained from CLEA Japan, Inc.) having an initial weight of 140 to 160 g were used as experimental animals. Rats were divided into 6 groups of 9 to 10 animals so that there was no difference in body weight between test groups (groups). All rats were individually housed in stainless steel cages at room temperature of 22 ± 2 ° C. with a light period of 7 to 19 o'clock and a dark period of 19 to 7 o'clock.
(1)ラットの水泳試験
実験動物には、初期体重が140~160gのSD系雄ラット(日本クレア株式会社より入手した)を用いた。ラットでは、試験区(群)ごとで体重差が生じないように、9~10尾ずつで6つに分けた。全てのラットは、明期7時~19時、暗期19時~7時として、室温の22±2℃の条件下にて、ステンレス製ケージ内で個体別に飼育された。 Example 1: Muscle synthesis promoting action by milk protein mixture (1) Rat swimming test SD male rats (obtained from CLEA Japan, Inc.) having an initial weight of 140 to 160 g were used as experimental animals. Rats were divided into 6 groups of 9 to 10 animals so that there was no difference in body weight between test groups (groups). All rats were individually housed in stainless steel cages at room temperature of 22 ± 2 ° C. with a light period of 7 to 19 o'clock and a dark period of 19 to 7 o'clock.
固形飼料(オリエンタル酵母工業株式会社製)を用いて、ラットを3~4日間で予備飼育し、以下のプロトコールに従って、ラットの水泳試験を行った(ラットに運動させた)。
Using a solid feed (Oriental Yeast Co., Ltd.), rats were preliminarily raised for 3 to 4 days, and the rats were subjected to a swimming test according to the following protocol (the rats were exercised).
[ラットの水泳試験(運動)のプロトコール]
1日目:ラットを重量負荷なしで、2時間の水泳運動、45分間の休憩、2時間の水泳運動の計4時間の水泳運動に供した。運動後の食餌(固形飼料MF)を自由摂取させた。
2日目:ラットを重量負荷なしで、3時間の水泳運動、45分間の休憩、3時間の水泳運動の計6時間の水泳運動に供した。運動後の食餌(固形飼料MF)を自由摂取させた。
3日目:ラットを重量負荷なしで、3時間の水泳運動、45分間の休憩、3時間の水泳運動の計6時間の水泳運動に供した。運動後の食餌として、5gの制限食(粉末飼料MF)を摂取させた。 [Rat swimming test (exercise) protocol]
Day 1: Rats were subjected to 2 hours of swimming exercise, 45 minutes of rest, 2 hours of swimming exercise for a total of 4 hours of swimming without weight load. The diet after exercise (solid feed MF) was freely taken.
Day 2: The rats were subjected to 3 hours of swimming exercise, 45 minutes of rest, 3 hours of swimming exercise for a total of 6 hours without weight load. The diet after exercise (solid feed MF) was freely taken.
Day 3: Rats were subjected to a total of 6 hours of swimming exercise without weight load, 3 hours of swimming exercise, 45 minutes of rest, 3 hours of swimming exercise. As a diet after exercise, 5 g of a restricted diet (powder feed MF) was ingested.
1日目:ラットを重量負荷なしで、2時間の水泳運動、45分間の休憩、2時間の水泳運動の計4時間の水泳運動に供した。運動後の食餌(固形飼料MF)を自由摂取させた。
2日目:ラットを重量負荷なしで、3時間の水泳運動、45分間の休憩、3時間の水泳運動の計6時間の水泳運動に供した。運動後の食餌(固形飼料MF)を自由摂取させた。
3日目:ラットを重量負荷なしで、3時間の水泳運動、45分間の休憩、3時間の水泳運動の計6時間の水泳運動に供した。運動後の食餌として、5gの制限食(粉末飼料MF)を摂取させた。 [Rat swimming test (exercise) protocol]
Day 1: Rats were subjected to 2 hours of swimming exercise, 45 minutes of rest, 2 hours of swimming exercise for a total of 4 hours of swimming without weight load. The diet after exercise (solid feed MF) was freely taken.
Day 2: The rats were subjected to 3 hours of swimming exercise, 45 minutes of rest, 3 hours of swimming exercise for a total of 6 hours without weight load. The diet after exercise (solid feed MF) was freely taken.
Day 3: Rats were subjected to a total of 6 hours of swimming exercise without weight load, 3 hours of swimming exercise, 45 minutes of rest, 3 hours of swimming exercise. As a diet after exercise, 5 g of a restricted diet (powder feed MF) was ingested.
上記の3日間の運動後に、ラットを重量負荷なしで、2時間の水泳運動に供した。そして、乳タンパク質および milliQ水を用いて、表1に示すタンパク質の濃度になるように、乳飲料(乳タンパク質溶液)を調製した。この3日間の運動後に、乳飲料および milliQ水を、24.24ml/kg BWで、ラットに経口摂取させた(試験区1~5および比較区1)。ここで、乳タンパク質には、乳タンパク質濃縮物(MPC480、フォンテラ社製、乳タンパク質 77.2重量%、乳脂肪分 1.2重量%、乳糖 9.2重量%、灰分 7.1重量%、水分 5.3重量%)を用いた。このMPC480は、脱脂乳を膜分離処理(UF処理、MF処理など)して、乳糖や灰分を除去し、カゼインタンパク質とホエイタンパク質とを主体として濃縮した、カゼインタンパク質とホエイタンパク質との混合物であり、その形態は、乾燥粉末である。そして、MPC480のタンパク質量比は、生乳(牛乳)と同様に、カゼインタンパク質:ホエイタンパク質=約8:2である(山内邦男および横山健吉編、ミルク総合辞典参照)。
After the above 3 days of exercise, the rats were subjected to a 2-hour swimming exercise without weight load. A milk beverage (milk protein solution) was prepared using milk protein and milliQ water so that the protein concentrations shown in Table 1 were obtained. After the exercise for 3 days, the rats were orally ingested milk drink and milliQ water at 24.24 ml / kg BW (test group 1-5 and comparative group 1). Here, the milk protein includes milk protein concentrate (MPC480, manufactured by Fontera, milk protein 77.2% by weight, milk fat content 1.2% by weight, lactose 9.2% by weight, ash content 7.1% by weight, Water (5.3 wt%) was used. This MPC480 is a mixture of casein protein and whey protein obtained by subjecting skim milk to membrane separation treatment (UF treatment, MF treatment, etc.), removing lactose and ash, and concentrating mainly on casein protein and whey protein. The form is a dry powder. And the protein amount ratio of MPC480 is casein protein: whey protein = about 8: 2 like raw milk (milk) (refer to Kunio Yamauchi and Kenkichi Yokoyama, Milk synthesis dictionary).
経口摂取から45分後に、尾静脈より体重の200gあたり、0.4mlの重水素ラベルフェニルアラニン溶液(重水素ラベルフェニルアラニン 22.5mgを生理食塩水 1mlに溶解して調製した)を注射した。注射から15分後に(すなわち、経口摂取から60分後に)、イソフルラン麻酔下において解剖した。腹部大静脈より全採血した後に、上肢三頭筋(サンプル)を摘出し、生理食塩水で洗浄し、直ちに液体窒素で凍結した。注射の時刻およびサンプルの凍結保存の時刻は正確に記録した。サンプルは分析時まで-80℃に保存した。
45 minutes after oral intake, 0.4 ml of deuterium labeled phenylalanine solution (prepared by dissolving 22.5 mg of deuterium labeled phenylalanine in 1 ml of physiological saline) per 200 g of body weight was injected from the tail vein. At 15 minutes after injection (ie, 60 minutes after oral ingestion), they were dissected under isoflurane anesthesia. After collecting all blood from the abdominal vena cava, the upper limb triceps (sample) was removed, washed with physiological saline, and immediately frozen with liquid nitrogen. The time of injection and the time of cryopreservation of the samples were recorded accurately. Samples were stored at −80 ° C. until analysis.
(2)骨格筋合成速度(FSR)の測定
先行文献(A. Kanda et al., Br J Nutr, Feb. 7, 1-7, 2013)の記載に基づいて、サンプルについて、骨格筋合成速度(FSR)を測定した。具体的には、LC/MS/MS(Waters社製)を用いて、骨格筋細胞中に存在する、あるいは骨格筋血液中に遊離状態で存在する、フェニルアラニン(Phe)および安定同位体標識フェニルアラニン(Phe(Ring-D5))を、それぞれ定量した。この測定条件は以下の通りである。すなわち、装置:LC/MS/MS(Waters社製)、カラム:ACQUITY UPLC BEH C18(Waters社製)、移動相:0.05%TFA水/0.05%TFA含有アセトニトリル、注入量 3μl、流速 0.3ml/min、UV 215nmである。 (2) Measurement of skeletal muscle synthesis rate (FSR) Based on the description in the previous literature (A. Kanda et al., Br J Nutr, Feb. 7, 1-7, 2013), skeletal muscle synthesis rate ( FSR) was measured. Specifically, using LC / MS / MS (manufactured by Waters), phenylalanine (Phe) and stable isotope labeled phenylalanine (present in skeletal muscle cells or free in skeletal muscle blood) Phe (Ring-D5)) was quantified. The measurement conditions are as follows. That is, apparatus: LC / MS / MS (manufactured by Waters), column: ACQUITY UPLC BEH C18 (manufactured by Waters), mobile phase: 0.05% TFA water / 0.05% TFA-containing acetonitrile,injection volume 3 μl, flow rate 0.3 ml / min, UV 215 nm.
先行文献(A. Kanda et al., Br J Nutr, Feb. 7, 1-7, 2013)の記載に基づいて、サンプルについて、骨格筋合成速度(FSR)を測定した。具体的には、LC/MS/MS(Waters社製)を用いて、骨格筋細胞中に存在する、あるいは骨格筋血液中に遊離状態で存在する、フェニルアラニン(Phe)および安定同位体標識フェニルアラニン(Phe(Ring-D5))を、それぞれ定量した。この測定条件は以下の通りである。すなわち、装置:LC/MS/MS(Waters社製)、カラム:ACQUITY UPLC BEH C18(Waters社製)、移動相:0.05%TFA水/0.05%TFA含有アセトニトリル、注入量 3μl、流速 0.3ml/min、UV 215nmである。 (2) Measurement of skeletal muscle synthesis rate (FSR) Based on the description in the previous literature (A. Kanda et al., Br J Nutr, Feb. 7, 1-7, 2013), skeletal muscle synthesis rate ( FSR) was measured. Specifically, using LC / MS / MS (manufactured by Waters), phenylalanine (Phe) and stable isotope labeled phenylalanine (present in skeletal muscle cells or free in skeletal muscle blood) Phe (Ring-D5)) was quantified. The measurement conditions are as follows. That is, apparatus: LC / MS / MS (manufactured by Waters), column: ACQUITY UPLC BEH C18 (manufactured by Waters), mobile phase: 0.05% TFA water / 0.05% TFA-containing acetonitrile,
ここで、以下の式により、骨格筋合成速度(FSR)を算出した。
FSR(%/日)=(Eb×100)/(Ea×t)
Ea:上清サンプルのエンリッチメント
Eb:骨格筋サンプルのエンリッチメント
t:注射溶液を注射してから、サンプルを凍結保存するまでの時間(単位:日)
エンリッチメント=Phe(Ring-D5)/(Phe+Phe(Ring-D5)) Here, the skeletal muscle synthesis rate (FSR) was calculated by the following equation.
FSR (% / day) = (Eb × 100) / (Ea × t)
Ea: Enrichment of supernatant sample Eb: Enrichment of skeletal muscle sample t: Time from injection of injection solution to cryopreservation of sample (unit: days)
Enrichment = Phe (Ring−D5) / (Phe + Phe (Ring−D5))
FSR(%/日)=(Eb×100)/(Ea×t)
Ea:上清サンプルのエンリッチメント
Eb:骨格筋サンプルのエンリッチメント
t:注射溶液を注射してから、サンプルを凍結保存するまでの時間(単位:日)
エンリッチメント=Phe(Ring-D5)/(Phe+Phe(Ring-D5)) Here, the skeletal muscle synthesis rate (FSR) was calculated by the following equation.
FSR (% / day) = (Eb × 100) / (Ea × t)
Ea: Enrichment of supernatant sample Eb: Enrichment of skeletal muscle sample t: Time from injection of injection solution to cryopreservation of sample (unit: days)
Enrichment = Phe (Ring−D5) / (Phe + Phe (Ring−D5))
この得られた数値を統計処理して、平均値±標準誤差を求めた。具体的には、一元配置の分散分析を行い、その後に、Tukeyの多重比較検定を行った。有意水準は5%未満とした(p<0.05)。この結果を図1に示す。図中で有意差がある場合には、異なる文字を付した。例えば、aが付された群(比較区1など)と、bが付された群(試験区3)またはcが付された群(試験区4など)とは、有意差があることを示している。また、例えば、a(比較区1など)またはb(試験区3)が付された群と、abが付された群(試験区2)とは、有意差がないことを示している。
The obtained numerical values were statistically processed to obtain an average value ± standard error. Specifically, a one-way analysis of variance was performed, followed by Tukey's multiple comparison test. The significance level was less than 5% (p <0.05). The result is shown in FIG. When there was a significant difference in the figure, different characters were attached. For example, it is shown that there is a significant difference between a group with a (comparison group 1 or the like) and a group with b (test group 3) or a group with c (test group 4 or the like). ing. Further, for example, it is shown that there is no significant difference between a group to which a (comparison group 1 or the like) or b (test group 3) is attached and a group to which ab is attached (test group 2).
このとき、乳タンパク質の経口摂取により、用量依存的に骨格筋合成が促進されることが確認された。
At this time, it was confirmed that skeletal muscle synthesis was promoted in a dose-dependent manner by oral intake of milk protein.
なお、2時間の水泳運動により、FSRが優位に低下することは、先行文献(A. Kanda et al., Br J Nutr, Feb. 7, 1-7, 2013)において確認されている(図2参照)。
In addition, it has been confirmed in the prior literature (A. Kanda et al., Br J Nutr, Feb. 7, 1-7, 2013) that the FSR is significantly reduced by two hours of swimming (Fig. 2). reference).
(3)血中3-メチルヒスチジン(3MeHis)濃度の測定
LC/MS/MS(Waster社製)を用いて、サンプルについて、骨格筋分解の指標の一つとして、血漿中3MeHis濃度を定量した。この測定条件は以下の通りである。すなわち、装置:LC/MS/MS(Waters社製)、カラム:ACQUITY UPLC BEH C18(Waters社製)、移動相:0.05% TFA水/0.05% TFA含有アセトニトリル、注入量 3μl、流速 0.3ml/minである。 (3) Measurement of blood 3-methylhistidine (3MeHis) concentration Using LC / MS / MS (manufactured by Water), the sample was quantified for plasma 3MeHis concentration as one of the indicators of skeletal muscle degradation. The measurement conditions are as follows. That is, apparatus: LC / MS / MS (manufactured by Waters), column: ACQUITY UPLC BEH C18 (manufactured by Waters), mobile phase: 0.05% TFA water / 0.05% TFA-containing acetonitrile,injection volume 3 μl, flow rate 0.3 ml / min.
LC/MS/MS(Waster社製)を用いて、サンプルについて、骨格筋分解の指標の一つとして、血漿中3MeHis濃度を定量した。この測定条件は以下の通りである。すなわち、装置:LC/MS/MS(Waters社製)、カラム:ACQUITY UPLC BEH C18(Waters社製)、移動相:0.05% TFA水/0.05% TFA含有アセトニトリル、注入量 3μl、流速 0.3ml/minである。 (3) Measurement of blood 3-methylhistidine (3MeHis) concentration Using LC / MS / MS (manufactured by Water), the sample was quantified for plasma 3MeHis concentration as one of the indicators of skeletal muscle degradation. The measurement conditions are as follows. That is, apparatus: LC / MS / MS (manufactured by Waters), column: ACQUITY UPLC BEH C18 (manufactured by Waters), mobile phase: 0.05% TFA water / 0.05% TFA-containing acetonitrile,
この得られた数値を統計処理して、平均値±標準誤差を求めた。具体的には、一元配置の分散分析を行い、その後に、Tukeyの多重比較検定を行った。有意水準は5%未満とした。この結果を図3に示す。図中で有意差がある場合には、異なる文字を付した。
The obtained numerical values were statistically processed to obtain an average value ± standard error. Specifically, a one-way analysis of variance was performed, followed by Tukey's multiple comparison test. The significance level was less than 5%. The result is shown in FIG. When there was a significant difference in the figure, different characters were attached.
このとき、乳タンパク質の経口摂取により、用量依存的に運動後の骨格筋分解が抑制されることが確認された。
At this time, it was confirmed that oral intake of milk protein suppressed skeletal muscle degradation after exercise in a dose-dependent manner.
実施例2:乳タンパク質を含む乳飲料による筋肉合成促進作用
(1)乳タンパク質を含む乳飲料の調製(製造)
生乳(乳タンパク質 3.3重量%、乳脂肪分 3.8重量%、乳糖 4.8重量%、灰分 0.7重量%、水分 87.4重量%、株式会社明治より入手した)に、乳タンパク質を添加して混合し、表2に示す乳タンパク質濃度になるように、原料乳を調製した。そして、常法の牛乳の製造方法に従って、プレート式熱交換器を用いた間接加熱方式により、130℃、2秒間で加熱殺菌してから、10℃以下に冷却することで、乳タンパク質を高濃度で含む乳飲料(乳タンパク質溶液)を得た(試験区6および7)。また、乳タンパク質を添加しない生乳(株式会社明治より入手した)にも、同様に加熱殺菌してから、10℃以下に冷却することで、牛乳を得た(試験区8)。ここで、乳飲料に添加した乳タンパク質には、乳タンパク質濃縮物(MPC480、フォンテラ社製、 乳タンパク質 77.2重量%、乳脂肪分 1.2重量%、乳糖 9.2重量%、灰分 7.1重量%、水分 5.3重量%)を用いた。このMPC480は、脱脂乳を膜分離処理(UF処理、MF処理など)して、乳糖や灰分を除去し、カゼインタンパク質とホエイタンパク質とを主体として濃縮した、カゼインタンパク質とホエイタンパク質との混合物であり、その形態は、乾燥粉末である。そして、MPC480のタンパク質量比は、生乳(牛乳)と同様に、カゼインタンパク質:ホエイタンパク質=約8:2である(山内邦男および横山健吉編、ミルク総合辞典参照)。 Example 2: Muscle synthesis promoting action by milk beverage containing milk protein (1) Preparation (production) of milk beverage containing milk protein
Raw milk (milk protein 3.3 wt%, milk fat 3.8 wt%, lactose 4.8 wt%, ash 0.7 wt%, moisture 87.4 wt%, obtained from Meiji Co., Ltd.) Protein was added and mixed to prepare raw milk so that the milk protein concentration shown in Table 2 was obtained. And according to the usual method for producing milk, the indirect heating method using a plate heat exchanger is sterilized by heating at 130 ° C. for 2 seconds, and then cooled to 10 ° C. or lower, so that the milk protein has a high concentration. (Milk test solution 6 and 7) was obtained. In addition, raw milk without milk protein (obtained from Meiji Co., Ltd.) was similarly heat sterilized and then cooled to 10 ° C. or lower to obtain milk (Test Section 8). Here, the milk protein added to the milk beverage includes milk protein concentrate (MPC480, manufactured by Fontera, milk protein 77.2% by weight, milk fat content 1.2% by weight, lactose 9.2% by weight, ash content 7 0.1 wt%, water 5.3 wt%). This MPC480 is a mixture of casein protein and whey protein obtained by subjecting skim milk to membrane separation treatment (UF treatment, MF treatment, etc.), removing lactose and ash, and concentrating mainly on casein protein and whey protein. The form is a dry powder. And the protein amount ratio of MPC480 is casein protein: whey protein = about 8: 2 like raw milk (milk) (refer to Kunio Yamauchi and Kenkichi Yokoyama, Milk synthesis dictionary).
(1)乳タンパク質を含む乳飲料の調製(製造)
生乳(乳タンパク質 3.3重量%、乳脂肪分 3.8重量%、乳糖 4.8重量%、灰分 0.7重量%、水分 87.4重量%、株式会社明治より入手した)に、乳タンパク質を添加して混合し、表2に示す乳タンパク質濃度になるように、原料乳を調製した。そして、常法の牛乳の製造方法に従って、プレート式熱交換器を用いた間接加熱方式により、130℃、2秒間で加熱殺菌してから、10℃以下に冷却することで、乳タンパク質を高濃度で含む乳飲料(乳タンパク質溶液)を得た(試験区6および7)。また、乳タンパク質を添加しない生乳(株式会社明治より入手した)にも、同様に加熱殺菌してから、10℃以下に冷却することで、牛乳を得た(試験区8)。ここで、乳飲料に添加した乳タンパク質には、乳タンパク質濃縮物(MPC480、フォンテラ社製、 乳タンパク質 77.2重量%、乳脂肪分 1.2重量%、乳糖 9.2重量%、灰分 7.1重量%、水分 5.3重量%)を用いた。このMPC480は、脱脂乳を膜分離処理(UF処理、MF処理など)して、乳糖や灰分を除去し、カゼインタンパク質とホエイタンパク質とを主体として濃縮した、カゼインタンパク質とホエイタンパク質との混合物であり、その形態は、乾燥粉末である。そして、MPC480のタンパク質量比は、生乳(牛乳)と同様に、カゼインタンパク質:ホエイタンパク質=約8:2である(山内邦男および横山健吉編、ミルク総合辞典参照)。 Example 2: Muscle synthesis promoting action by milk beverage containing milk protein (1) Preparation (production) of milk beverage containing milk protein
Raw milk (milk protein 3.3 wt%, milk fat 3.8 wt%, lactose 4.8 wt%, ash 0.7 wt%, moisture 87.4 wt%, obtained from Meiji Co., Ltd.) Protein was added and mixed to prepare raw milk so that the milk protein concentration shown in Table 2 was obtained. And according to the usual method for producing milk, the indirect heating method using a plate heat exchanger is sterilized by heating at 130 ° C. for 2 seconds, and then cooled to 10 ° C. or lower, so that the milk protein has a high concentration. (
これら得られた乳飲料および牛乳では何れも、加熱に伴うタンパク質の凝集(固化)により生じる沈殿物は見られなかった。
In any of these milk drinks and milk obtained, no precipitates were observed due to protein aggregation (solidification) upon heating.
(2)ラットの水泳試験および骨格筋合成速度(FSR)の測定
表2に示す生乳(試験区8)、乳飲料(試験区6および7)および milliQ水(比較区1)を、24.24ml/kg BWで、ラットに経口摂取させた以外には、上記の実施例1に記載の方法と同様に、ラットの水泳試験を行った。その後に、骨格筋合成速度(FSR)を測定(算出)した。 (2) Rat swimming test and measurement of skeletal muscle synthesis rate (FSR) 24.24 ml of raw milk (test group 8), milk drink (test group 6 and 7) and milliQ water (comparative group 1) shown in Table 2 A rat swimming test was conducted in the same manner as described in Example 1 except that the rat was orally ingested at / kg BW. Thereafter, the skeletal muscle synthesis rate (FSR) was measured (calculated).
表2に示す生乳(試験区8)、乳飲料(試験区6および7)および milliQ水(比較区1)を、24.24ml/kg BWで、ラットに経口摂取させた以外には、上記の実施例1に記載の方法と同様に、ラットの水泳試験を行った。その後に、骨格筋合成速度(FSR)を測定(算出)した。 (2) Rat swimming test and measurement of skeletal muscle synthesis rate (FSR) 24.24 ml of raw milk (test group 8), milk drink (
その結果、試験区6および7のFSRは、それぞれ6.7%/日および7.7%/日と高いものであった。
As a result, the FSRs of test sections 6 and 7 were as high as 6.7% / day and 7.7% / day, respectively.
このとき、試験区6および7では、ホエイタンパク質を単独で経口摂取した場合と同等に、即効的な筋肉合成促進作用が確認された。
At this time, in the test sections 6 and 7, an immediate effect of promoting muscle synthesis was confirmed as in the case of taking whey protein alone orally.
なお、2時間のトレッドミルの運動後に、ホエイタンパク質をタンパク質量として、3.11g/kg BWで経口摂取した場合に、FSRが8.8%/日であることは、先行文献(Anthony et al., J. Nutr. 137, 357-362 (2007))において確認されている。
It should be noted that the FSR is 8.8% / day when whey protein is taken orally at 3.11 g / kg BW after 2 hours of treadmill exercise as a protein amount. , J. Nutr. 137, 357-362 (2007)).
Claims (17)
- カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を有効成分として含んでなる、タンパク質の即時吸収を必要とする対象のための筋肉合成促進剤であって、ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である筋肉合成促進剤。 A muscle synthesis promoter for a subject in need of immediate absorption of protein, comprising a milk protein mixture containing casein protein and whey protein as an active ingredient, wherein the protein amount ratio of casein protein to whey protein (casein (Protein / whey protein) is a muscle synthesis promoter having 2-20.
- 前記乳タンパク質混合物が総タンパク質量で一食あたり0.13~0.7g/kg体重となるように摂取される、請求項1に記載の筋肉合成促進剤。 The muscle synthesis promoter according to claim 1, wherein the milk protein mixture is ingested so that a total protein amount is 0.13 to 0.7 g / kg body weight per meal.
- 一食あたりの単位包装形態からなり、該単位包装形態中に、前記乳タンパク質混合物を一食摂取量として総タンパク質量で8~40gに調整してなる、請求項1または2に記載の筋肉合成促進剤。 The muscle synthesis promotion according to claim 1 or 2, comprising a unit packaging form per serving, wherein the milk protein mixture is adjusted to 8 to 40 g in terms of a total protein amount in a unit packaging form. Agent.
- タンパク質の即時吸収を必要とする対象が、運動する対象である、請求項1~3のいずれか一項に記載の筋肉合成促進剤。 The muscle synthesis promoter according to any one of claims 1 to 3, wherein the subject requiring immediate protein absorption is a subject to exercise.
- 運動が筋肉トレーニングである、請求項4に記載の筋肉合成促進剤。 The muscle synthesis promoter according to claim 4, wherein the exercise is muscle training.
- 液状形態である、請求項1~5のいずれか一項に記載の筋肉合成促進剤。 The muscle synthesis promoter according to any one of claims 1 to 5, which is in a liquid form.
- 請求項1~6のいずれか一項に記載の筋肉合成促進剤を配合および加熱殺菌してなる飲食品であって、一食あたりの単位包装形態からなり、該単位包装形態中に、前記乳タンパク質混合物を一食摂取量として総タンパク質量で8~40gに調整してなる、タンパク質の即時吸収による筋肉合成促進作用が付与された、包装容器詰の飲食品。 A food and drink comprising the muscle synthesis promoter according to any one of claims 1 to 6 blended and heat-sterilized, comprising a unit packaging form per serving, wherein the milk protein is contained in the unit packaging form. A food and drink packaged in a packaged container, with the effect of promoting muscle synthesis by immediate absorption of protein, wherein the mixture is adjusted to 8 to 40 g in terms of the total protein intake.
- ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、生乳、殺菌乳、濃縮乳、粉乳および還元乳からなる群から選択される一種以上と混合および加熱殺菌してなる乳飲料であって、前記乳タンパク質混合物を総タンパク質量で8g以上/200mlおよび乳脂肪量を8g以下/200mlに調整してなる、タンパク質の即時吸収による筋肉合成促進作用が付与された、包装容器詰の乳飲料。 A milk protein mixture containing casein protein and whey protein having a protein content ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is composed of raw milk, pasteurized milk, concentrated milk, powdered milk and reduced milk. A milk beverage obtained by mixing and heat-sterilizing with at least one selected from the group, wherein the milk protein mixture is adjusted to a total protein amount of 8 g / 200 ml and a milk fat amount of 8 g / 200 ml / ml. Packed container-packed dairy drink with added muscle synthesis-promoting action by immediate absorption.
- ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、生乳、殺菌乳、濃縮乳、粉乳および還元乳からなる群から選択される一種以上に添加する工程、および加熱殺菌する工程を含んでなる、包装容器詰の乳飲料の製造方法であって、前記乳タンパク質混合物を総タンパク質量で8g以上/200mlおよび乳脂肪量を8g以下/200mlに調整してなる、タンパク質の即時吸収による筋肉合成促進作用が付与された、包装容器詰の乳飲料の製造方法。 A milk protein mixture containing casein protein and whey protein having a protein content ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is composed of raw milk, pasteurized milk, concentrated milk, powdered milk and reduced milk. A method for producing a packaging container-packed milk beverage comprising the step of adding to one or more selected from the group and the step of heat sterilization, wherein the milk protein mixture is 8 g / 200 ml in total protein and milk A method for producing a packaged-packed milk beverage, which is provided with an effect of promoting muscle synthesis by immediate protein absorption, wherein the fat amount is adjusted to 8 g or less / 200 ml.
- ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、タンパク質の即時吸収を必要とする対象に摂取させることを含んでなる、筋肉合成促進方法(ヒトに対する医療行為を除く)。 A milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is to be ingested by a subject who needs immediate absorption of the protein. A method for promoting muscle synthesis, comprising medical treatment for humans.
- ホエイタンパク質に対するカゼインタンパク質のタンパク質量比(カゼインタンパク質/ホエイタンパク質)が2~20である、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を、タンパク質の即時吸収を必要とする対象に摂取させることを含んでなる、筋肉合成促進方法。 A milk protein mixture containing casein protein and whey protein having a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20 is to be ingested by a subject who needs immediate absorption of the protein. A method for promoting muscle synthesis, comprising:
- 前記乳タンパク質混合物を総タンパク質量で一食あたり0.13~0.7g/kg体重となるように摂取させる、請求項10または11に記載の筋肉合成促進方法。 The method for promoting muscle synthesis according to claim 10 or 11, wherein the milk protein mixture is ingested so that the total protein amount is 0.13 to 0.7 g / kg body weight per meal.
- 前記乳タンパク質混合物を、乳タンパク質混合物の総タンパク質量で一食あたり8~40gとなるように摂取させる、請求項12に記載の筋肉合成促進方法。 The method for promoting muscle synthesis according to claim 12, wherein the milk protein mixture is ingested so that the total protein amount of the milk protein mixture is 8 to 40 g per serving.
- 前記乳タンパク質混合物を、タンパク質の即時吸収を必要する対象に加温液状形態で摂取させることを含んでなる、請求項10~13のいずれか一項に記載の筋肉合成促進方法。 The method for promoting muscle synthesis according to any one of claims 10 to 13, comprising ingesting the milk protein mixture in a heated liquid form to a subject in need of immediate protein absorption.
- タンパク質の即時吸収を必要とする対象が運動する対象である、請求項10~14のいずれか一項に記載の筋肉合成促進方法。 The method for promoting muscle synthesis according to any one of claims 10 to 14, wherein a subject requiring immediate absorption of protein is a subject to exercise.
- 運動する対象が運動直後の対象である、請求項15に記載の筋肉合成促進方法。 The method for promoting muscle synthesis according to claim 15, wherein the subject to exercise is a subject immediately after exercise.
- 運動が筋肉トレーニングである、請求項15または16に記載の筋肉合成促進方法。 The method for promoting muscle synthesis according to claim 15 or 16, wherein the exercise is muscle training.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480050083.3A CN105658231A (en) | 2013-09-12 | 2014-09-12 | Muscle repair promoter |
JP2015536652A JPWO2015037720A1 (en) | 2013-09-12 | 2014-09-12 | Muscle synthesis promoter |
SG11201601774VA SG11201601774VA (en) | 2013-09-12 | 2014-09-12 | Muscle synthesis promoter |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-189703 | 2013-09-12 | ||
JP2013189703 | 2013-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015037720A1 true WO2015037720A1 (en) | 2015-03-19 |
Family
ID=52665816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/074291 WO2015037720A1 (en) | 2013-09-12 | 2014-09-12 | Muscle repair promoter |
Country Status (4)
Country | Link |
---|---|
JP (1) | JPWO2015037720A1 (en) |
CN (1) | CN105658231A (en) |
SG (1) | SG11201601774VA (en) |
WO (1) | WO2015037720A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016121923A1 (en) * | 2015-01-29 | 2016-08-04 | 株式会社明治 | Muscle synthesis promoter |
WO2017026429A1 (en) * | 2015-08-10 | 2017-02-16 | 株式会社明治 | Muscle synthesis promoting agent |
WO2018164251A1 (en) * | 2017-03-10 | 2018-09-13 | 株式会社明治 | Composition for improving physical strength |
WO2019124355A1 (en) * | 2017-12-18 | 2019-06-27 | 株式会社明治 | Muscle-synthesis-promoting fermented milk |
WO2020013307A1 (en) * | 2018-07-13 | 2020-01-16 | 株式会社明治 | Method for producing concentrated yogurt |
JP2020014452A (en) * | 2018-07-13 | 2020-01-30 | 株式会社明治 | Method for producing concentrated fermented milk |
WO2020085409A1 (en) * | 2018-10-25 | 2020-04-30 | 味の素株式会社 | Body enhancing agent |
US20210329949A1 (en) * | 2020-04-27 | 2021-10-28 | Leprino Performance Brands LLC | Protein-fortified beverages for enhanced athletic performance |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI761487B (en) * | 2017-04-06 | 2022-04-21 | 日商明治股份有限公司 | Fermented milk used to increase blood amino acid concentration |
CN114431380A (en) * | 2022-02-25 | 2022-05-06 | 广东君悦营养医学有限公司 | A kind of protein water suitable for sarcopenia syndrome and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012110705A1 (en) * | 2011-02-18 | 2012-08-23 | Valio Ltd | Milk-based product and a method for its preparation |
JP2013517808A (en) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | Nutritional emulsion containing calcium HMB |
JP2013517807A (en) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | Plastic packaging nutrient solution containing HMB |
-
2014
- 2014-09-12 JP JP2015536652A patent/JPWO2015037720A1/en active Pending
- 2014-09-12 WO PCT/JP2014/074291 patent/WO2015037720A1/en active Application Filing
- 2014-09-12 CN CN201480050083.3A patent/CN105658231A/en active Pending
- 2014-09-12 SG SG11201601774VA patent/SG11201601774VA/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013517808A (en) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | Nutritional emulsion containing calcium HMB |
JP2013517807A (en) * | 2010-01-29 | 2013-05-20 | アボット・ラボラトリーズ | Plastic packaging nutrient solution containing HMB |
WO2012110705A1 (en) * | 2011-02-18 | 2012-08-23 | Valio Ltd | Milk-based product and a method for its preparation |
Non-Patent Citations (2)
Title |
---|
DAICHI NAKAJIMA ET AL.: "Effect of total milk proteins ingestion on muscle mass and body fat", FOOD STYLE 21, vol. 16, no. 9, 2012, pages 76 - 78 * |
TAKAYUKI KITAGISHI ET AL.: "Intake of total milk proteins and prevention of sarcopenia", FOOD STYLE 21, vol. 17, no. 4, 1 April 2013 (2013-04-01), pages 56 - 58 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016121923A1 (en) * | 2015-01-29 | 2016-08-04 | 株式会社明治 | Muscle synthesis promoter |
WO2017026429A1 (en) * | 2015-08-10 | 2017-02-16 | 株式会社明治 | Muscle synthesis promoting agent |
JPWO2017026429A1 (en) * | 2015-08-10 | 2018-05-31 | 株式会社明治 | Muscle synthesis promoter |
WO2018164251A1 (en) * | 2017-03-10 | 2018-09-13 | 株式会社明治 | Composition for improving physical strength |
WO2019124355A1 (en) * | 2017-12-18 | 2019-06-27 | 株式会社明治 | Muscle-synthesis-promoting fermented milk |
JPWO2019124355A1 (en) * | 2017-12-18 | 2020-12-10 | 株式会社明治 | Fermented milk for promoting muscle synthesis |
WO2020013307A1 (en) * | 2018-07-13 | 2020-01-16 | 株式会社明治 | Method for producing concentrated yogurt |
JP2020014452A (en) * | 2018-07-13 | 2020-01-30 | 株式会社明治 | Method for producing concentrated fermented milk |
WO2020085409A1 (en) * | 2018-10-25 | 2020-04-30 | 味の素株式会社 | Body enhancing agent |
US20210329949A1 (en) * | 2020-04-27 | 2021-10-28 | Leprino Performance Brands LLC | Protein-fortified beverages for enhanced athletic performance |
Also Published As
Publication number | Publication date |
---|---|
SG11201601774VA (en) | 2016-04-28 |
CN105658231A (en) | 2016-06-08 |
JPWO2015037720A1 (en) | 2017-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015037720A1 (en) | Muscle repair promoter | |
JP6728071B2 (en) | Muscle synthesis promoter | |
JP7108521B2 (en) | Composition for promoting an increase in the amount of BDNF in the body | |
US20050112177A1 (en) | Nutritional supplement composition and method | |
WO2017026429A1 (en) | Muscle synthesis promoting agent | |
US20060062827A1 (en) | Nutritional supplement composition and method | |
US20050112176A1 (en) | Nutritional supplement composition and method | |
JP6037595B2 (en) | Satiety induction composition and method for producing the same | |
JP2019031466A (en) | Composition for inhibiting or improving hyperglycemia | |
JP6430386B2 (en) | Body moisture retention agent | |
WO2017060663A1 (en) | Compositions | |
WO2016133036A1 (en) | Fatigue ameliorating agent | |
WO2018123873A1 (en) | Composition for promoting perspiration | |
CN117255621A (en) | Nutritional compositions and methods relating thereto | |
WO2018164251A1 (en) | Composition for improving physical strength | |
WO2018139624A1 (en) | Composition for promoting insulin secretion | |
WO2018074415A1 (en) | Composition for improving protein efficiency ratio | |
JP2019024389A (en) | Amino acid composition for improved muscle strength |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14844506 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015536652 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14844506 Country of ref document: EP Kind code of ref document: A1 |